CN115770292A - 新型冠状病毒SARS-CoV-2的协同免疫及其用途 - Google Patents
新型冠状病毒SARS-CoV-2的协同免疫及其用途 Download PDFInfo
- Publication number
- CN115770292A CN115770292A CN202111051170.9A CN202111051170A CN115770292A CN 115770292 A CN115770292 A CN 115770292A CN 202111051170 A CN202111051170 A CN 202111051170A CN 115770292 A CN115770292 A CN 115770292A
- Authority
- CN
- China
- Prior art keywords
- vaccine
- mutant
- cov
- sars
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001678559 COVID-19 virus Species 0.000 title claims abstract description 37
- 230000003053 immunization Effects 0.000 title abstract description 52
- 238000002649 immunization Methods 0.000 title abstract description 45
- 230000002195 synergetic effect Effects 0.000 title abstract description 10
- 229960005486 vaccine Drugs 0.000 claims abstract description 337
- 241000711573 Coronaviridae Species 0.000 claims abstract description 42
- 241000700605 Viruses Species 0.000 claims abstract description 39
- 239000013066 combination product Substances 0.000 claims abstract description 7
- 229940127555 combination product Drugs 0.000 claims abstract description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 70
- 230000037452 priming Effects 0.000 claims description 65
- 108020001507 fusion proteins Proteins 0.000 claims description 47
- 102000037865 fusion proteins Human genes 0.000 claims description 47
- 150000007523 nucleic acids Chemical class 0.000 claims description 36
- 210000004027 cell Anatomy 0.000 claims description 33
- 108020004707 nucleic acids Proteins 0.000 claims description 33
- 102000039446 nucleic acids Human genes 0.000 claims description 33
- 201000010099 disease Diseases 0.000 claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims description 30
- 102000014150 Interferons Human genes 0.000 claims description 28
- 108010050904 Interferons Proteins 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 28
- 229940079322 interferon Drugs 0.000 claims description 27
- 102100031673 Corneodesmosin Human genes 0.000 claims description 26
- 101710139375 Corneodesmosin Proteins 0.000 claims description 26
- 239000012634 fragment Substances 0.000 claims description 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 24
- 229920001184 polypeptide Polymers 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 19
- 241000282414 Homo sapiens Species 0.000 claims description 17
- 239000013604 expression vector Substances 0.000 claims description 17
- 239000002773 nucleotide Substances 0.000 claims description 16
- 125000003729 nucleotide group Chemical group 0.000 claims description 16
- 108060003951 Immunoglobulin Proteins 0.000 claims description 15
- 239000003085 diluting agent Substances 0.000 claims description 15
- 239000003937 drug carrier Substances 0.000 claims description 15
- 102000018358 immunoglobulin Human genes 0.000 claims description 15
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 15
- 241000701161 unidentified adenovirus Species 0.000 claims description 14
- 239000000839 emulsion Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000013598 vector Substances 0.000 claims description 10
- 108010074328 Interferon-gamma Proteins 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 102000008070 Interferon-gamma Human genes 0.000 claims description 8
- 241001493065 dsRNA viruses Species 0.000 claims description 8
- 230000028993 immune response Effects 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 108020004414 DNA Proteins 0.000 claims description 7
- 102000002227 Interferon Type I Human genes 0.000 claims description 7
- 108010014726 Interferon Type I Proteins 0.000 claims description 7
- 102100040018 Interferon alpha-2 Human genes 0.000 claims description 7
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 7
- -1 Quil a Chemical compound 0.000 claims description 6
- 108010018844 interferon type III Proteins 0.000 claims description 6
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 5
- 102000053602 DNA Human genes 0.000 claims description 5
- 241000713666 Lentivirus Species 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000000443 aerosol Substances 0.000 claims description 5
- 241001430294 unidentified retrovirus Species 0.000 claims description 5
- 239000013603 viral vector Substances 0.000 claims description 5
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 239000003595 mist Substances 0.000 claims description 4
- 239000013612 plasmid Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 241001446316 Bohle iridovirus Species 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 3
- 241000178270 Canarypox virus Species 0.000 claims description 3
- 241000713756 Caprine arthritis encephalitis virus Species 0.000 claims description 3
- 241000701022 Cytomegalovirus Species 0.000 claims description 3
- 241000713730 Equine infectious anemia virus Species 0.000 claims description 3
- 241000713800 Feline immunodeficiency virus Species 0.000 claims description 3
- 241000710831 Flavivirus Species 0.000 claims description 3
- 241000700662 Fowlpox virus Species 0.000 claims description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 3
- 241000714192 Human spumaretrovirus Species 0.000 claims description 3
- 108010078049 Interferon alpha-2 Proteins 0.000 claims description 3
- 241000714209 Norwalk virus Species 0.000 claims description 3
- 241000282577 Pan troglodytes Species 0.000 claims description 3
- 241001494479 Pecora Species 0.000 claims description 3
- 241000702263 Reovirus sp. Species 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 241000700584 Simplexvirus Species 0.000 claims description 3
- 241000700618 Vaccinia virus Species 0.000 claims description 3
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 231100000283 hepatitis Toxicity 0.000 claims description 3
- 229960003130 interferon gamma Drugs 0.000 claims description 3
- 108020004999 messenger RNA Proteins 0.000 claims description 3
- 241000701447 unidentified baculovirus Species 0.000 claims description 3
- 241001529453 unidentified herpesvirus Species 0.000 claims description 3
- 241000710929 Alphavirus Species 0.000 claims description 2
- 108020004638 Circular DNA Proteins 0.000 claims description 2
- 108091028075 Circular RNA Proteins 0.000 claims description 2
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 241000941423 Grom virus Species 0.000 claims description 2
- 241000238631 Hexapoda Species 0.000 claims description 2
- 241001529936 Murinae Species 0.000 claims description 2
- 241000709664 Picornaviridae Species 0.000 claims description 2
- 241000125945 Protoparvovirus Species 0.000 claims description 2
- 206010037742 Rabies Diseases 0.000 claims description 2
- 241000711798 Rabies lyssavirus Species 0.000 claims description 2
- NKVLDFAVEWLOCX-GUSKIFEASA-N [(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-4,5-dihydroxy-6-methyloxan-2-yl] (4ar,5r,6as,6br,9s,10s,12ar)-10-[(2r,3r,4s, Chemical compound O([C@H]1[C@H](O)CO[C@H]([C@@H]1O)O[C@H]1[C@H](C)O[C@H]([C@@H]([C@@H]1O)O)O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](C)O[C@H]1OC(=O)[C@]12CCC(C)(C)CC1C1=CCC3[C@@]([C@@]1(C[C@H]2O)C)(C)CCC1[C@]3(C)CC[C@@H]([C@@]1(C)C=O)O[C@@H]1O[C@@H]([C@H]([C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)CO2)O)[C@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O)C(=O)NCCCCCCCCCCCC)[C@@H]1OC[C@](O)(CO)[C@H]1O NKVLDFAVEWLOCX-GUSKIFEASA-N 0.000 claims description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 2
- 208000004668 avian leukosis Diseases 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
- 230000003210 demyelinating effect Effects 0.000 claims description 2
- 229930182490 saponin Natural products 0.000 claims description 2
- 150000007949 saponins Chemical class 0.000 claims description 2
- 235000017709 saponins Nutrition 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 210000005253 yeast cell Anatomy 0.000 claims description 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 12
- 102000006992 Interferon-alpha Human genes 0.000 claims 12
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 12
- 241000272525 Anas platyrhynchos Species 0.000 claims 1
- 241000282465 Canis Species 0.000 claims 1
- 241000283073 Equus caballus Species 0.000 claims 1
- 241000282324 Felis Species 0.000 claims 1
- 241000287828 Gallus gallus Species 0.000 claims 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 claims 1
- 229940001007 aluminium phosphate Drugs 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 239000007789 gas Substances 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 15
- 230000036039 immunity Effects 0.000 abstract description 6
- 230000001681 protective effect Effects 0.000 abstract description 5
- 230000007123 defense Effects 0.000 abstract description 4
- 229940000425 combination drug Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 47
- 241001112090 Pseudovirus Species 0.000 description 38
- 238000002347 injection Methods 0.000 description 18
- 239000007924 injection Substances 0.000 description 18
- 239000000843 powder Substances 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 238000009472 formulation Methods 0.000 description 16
- 210000002414 leg Anatomy 0.000 description 16
- 208000024891 symptom Diseases 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 238000007911 parenteral administration Methods 0.000 description 11
- 241000880493 Leptailurus serval Species 0.000 description 10
- 238000006386 neutralization reaction Methods 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 7
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 7
- XTDDIVQWDXMRJL-IHRRRGAJSA-N Val-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C(C)C)N XTDDIVQWDXMRJL-IHRRRGAJSA-N 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 108010051242 phenylalanylserine Proteins 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- NBTGEURICRTMGL-WHFBIAKZSA-N Ala-Gly-Ser Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O NBTGEURICRTMGL-WHFBIAKZSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- QPJSIBAOZBVELU-BPNCWPANSA-N Val-Tyr-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C(C)C)N QPJSIBAOZBVELU-BPNCWPANSA-N 0.000 description 6
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108010092854 aspartyllysine Proteins 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- UGXVKHRDGLYFKR-CIUDSAMLSA-N Asn-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(N)=O UGXVKHRDGLYFKR-CIUDSAMLSA-N 0.000 description 5
- 208000025721 COVID-19 Diseases 0.000 description 5
- 101000959794 Homo sapiens Interferon alpha-2 Proteins 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- SQHKXWODKJDZRC-LKXGYXEUSA-N Ser-Thr-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O SQHKXWODKJDZRC-LKXGYXEUSA-N 0.000 description 5
- SCCKSNREWHMKOJ-SRVKXCTJSA-N Tyr-Asn-Ser Chemical compound N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O SCCKSNREWHMKOJ-SRVKXCTJSA-N 0.000 description 5
- 108010087924 alanylproline Proteins 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 229940031416 bivalent vaccine Drugs 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- KUDREHRZRIVKHS-UWJYBYFXSA-N Ala-Asp-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KUDREHRZRIVKHS-UWJYBYFXSA-N 0.000 description 4
- VRTOMXFZHGWHIJ-KZVJFYERSA-N Ala-Thr-Arg Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O VRTOMXFZHGWHIJ-KZVJFYERSA-N 0.000 description 4
- JCAISGGAOQXEHJ-ZPFDUUQYSA-N Arg-Gln-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N JCAISGGAOQXEHJ-ZPFDUUQYSA-N 0.000 description 4
- LXMKTIZAGIBQRX-HRCADAONSA-N Arg-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O LXMKTIZAGIBQRX-HRCADAONSA-N 0.000 description 4
- SQZIAWGBBUSSPJ-ZKWXMUAHSA-N Asn-Cys-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(=O)N)N SQZIAWGBBUSSPJ-ZKWXMUAHSA-N 0.000 description 4
- IBLAOXSULLECQZ-IUKAMOBKSA-N Asn-Ile-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC(N)=O IBLAOXSULLECQZ-IUKAMOBKSA-N 0.000 description 4
- BXUHCIXDSWRSBS-CIUDSAMLSA-N Asn-Leu-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O BXUHCIXDSWRSBS-CIUDSAMLSA-N 0.000 description 4
- FODVBOKTYKYRFJ-CIUDSAMLSA-N Asn-Lys-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)N)N FODVBOKTYKYRFJ-CIUDSAMLSA-N 0.000 description 4
- SVFOIXMRMLROHO-SRVKXCTJSA-N Asp-Asp-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SVFOIXMRMLROHO-SRVKXCTJSA-N 0.000 description 4
- HPZAJRPYUIHDIN-BZSNNMDCSA-N Cys-Tyr-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CS)N HPZAJRPYUIHDIN-BZSNNMDCSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- UWMDGPFFTKDUIY-HJGDQZAQSA-N Gln-Pro-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O UWMDGPFFTKDUIY-HJGDQZAQSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- GNXGAVNTVNOCLL-SIUGBPQLSA-N Ile-Tyr-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N GNXGAVNTVNOCLL-SIUGBPQLSA-N 0.000 description 4
- UGTHTQWIQKEDEH-BQBZGAKWSA-N L-alanyl-L-prolylglycine zwitterion Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UGTHTQWIQKEDEH-BQBZGAKWSA-N 0.000 description 4
- YPLVCBKEPJPBDQ-MELADBBJSA-N Lys-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N YPLVCBKEPJPBDQ-MELADBBJSA-N 0.000 description 4
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 4
- UHRNIXJAGGLKHP-DLOVCJGASA-N Phe-Ala-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O UHRNIXJAGGLKHP-DLOVCJGASA-N 0.000 description 4
- YYRCPTVAPLQRNC-ULQDDVLXSA-N Phe-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC1=CC=CC=C1 YYRCPTVAPLQRNC-ULQDDVLXSA-N 0.000 description 4
- JHSRGEODDALISP-XVSYOHENSA-N Phe-Thr-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O JHSRGEODDALISP-XVSYOHENSA-N 0.000 description 4
- GURGCNUWVSDYTP-SRVKXCTJSA-N Pro-Leu-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O GURGCNUWVSDYTP-SRVKXCTJSA-N 0.000 description 4
- FIDMVVBUOCMMJG-CIUDSAMLSA-N Ser-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO FIDMVVBUOCMMJG-CIUDSAMLSA-N 0.000 description 4
- PMCMLDNPAZUYGI-DCAQKATOSA-N Ser-Lys-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O PMCMLDNPAZUYGI-DCAQKATOSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- NSTPFWRAIDTNGH-BZSNNMDCSA-N Tyr-Asn-Tyr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O NSTPFWRAIDTNGH-BZSNNMDCSA-N 0.000 description 4
- QGFPYRPIUXBYGR-YDHLFZDLSA-N Val-Asn-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N QGFPYRPIUXBYGR-YDHLFZDLSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 4
- 238000010009 beating Methods 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 4
- 108010001064 glycyl-glycyl-glycyl-glycine Proteins 0.000 description 4
- 108010037850 glycylvaline Proteins 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 108010012581 phenylalanylglutamate Proteins 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108010051110 tyrosyl-lysine Proteins 0.000 description 4
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 3
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 3
- KQFRUSHJPKXBMB-BHDSKKPTSA-N Ala-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)C)C(O)=O)=CNC2=C1 KQFRUSHJPKXBMB-BHDSKKPTSA-N 0.000 description 3
- MIPWEZAIMPYQST-FXQIFTODSA-N Ala-Cys-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O MIPWEZAIMPYQST-FXQIFTODSA-N 0.000 description 3
- GGNHBHYDMUDXQB-KBIXCLLPSA-N Ala-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)N GGNHBHYDMUDXQB-KBIXCLLPSA-N 0.000 description 3
- BMNVSPMWMICFRV-DCAQKATOSA-N Arg-His-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(O)=O)CC1=CN=CN1 BMNVSPMWMICFRV-DCAQKATOSA-N 0.000 description 3
- HJDNZFIYILEIKR-OSUNSFLBSA-N Arg-Ile-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O HJDNZFIYILEIKR-OSUNSFLBSA-N 0.000 description 3
- RYQSYXFGFOTJDJ-RHYQMDGZSA-N Arg-Thr-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O RYQSYXFGFOTJDJ-RHYQMDGZSA-N 0.000 description 3
- SLKLLQWZQHXYSV-CIUDSAMLSA-N Asn-Ala-Lys Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O SLKLLQWZQHXYSV-CIUDSAMLSA-N 0.000 description 3
- QPTAGIPWARILES-AVGNSLFASA-N Asn-Gln-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QPTAGIPWARILES-AVGNSLFASA-N 0.000 description 3
- OLVIPTLKNSAYRJ-YUMQZZPRSA-N Asn-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N OLVIPTLKNSAYRJ-YUMQZZPRSA-N 0.000 description 3
- OOWSBIOUKIUWLO-RCOVLWMOSA-N Asn-Gly-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O OOWSBIOUKIUWLO-RCOVLWMOSA-N 0.000 description 3
- JEEFEQCRXKPQHC-KKUMJFAQSA-N Asn-Leu-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JEEFEQCRXKPQHC-KKUMJFAQSA-N 0.000 description 3
- XDGBFDYXZCMYEX-NUMRIWBASA-N Asp-Glu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)N)O XDGBFDYXZCMYEX-NUMRIWBASA-N 0.000 description 3
- WSGVTKZFVJSJOG-RCOVLWMOSA-N Asp-Gly-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O WSGVTKZFVJSJOG-RCOVLWMOSA-N 0.000 description 3
- KTTCQQNRRLCIBC-GHCJXIJMSA-N Asp-Ile-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O KTTCQQNRRLCIBC-GHCJXIJMSA-N 0.000 description 3
- AHWRSSLYSGLBGD-CIUDSAMLSA-N Asp-Pro-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O AHWRSSLYSGLBGD-CIUDSAMLSA-N 0.000 description 3
- MGSVBZIBCCKGCY-ZLUOBGJFSA-N Asp-Ser-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MGSVBZIBCCKGCY-ZLUOBGJFSA-N 0.000 description 3
- YUELDQUPTAYEGM-XIRDDKMYSA-N Asp-Trp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC(=O)O)N YUELDQUPTAYEGM-XIRDDKMYSA-N 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- OJQJUQUBJGTCRY-WFBYXXMGSA-N Cys-Ala-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CS)N OJQJUQUBJGTCRY-WFBYXXMGSA-N 0.000 description 3
- XABFFGOGKOORCG-CIUDSAMLSA-N Cys-Asp-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O XABFFGOGKOORCG-CIUDSAMLSA-N 0.000 description 3
- 108010090461 DFG peptide Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- AJDMYLOISOCHHC-YVNDNENWSA-N Gln-Gln-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O AJDMYLOISOCHHC-YVNDNENWSA-N 0.000 description 3
- KVXVVDFOZNYYKZ-DCAQKATOSA-N Gln-Gln-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O KVXVVDFOZNYYKZ-DCAQKATOSA-N 0.000 description 3
- ITYRYNUZHPNCIK-GUBZILKMSA-N Glu-Ala-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O ITYRYNUZHPNCIK-GUBZILKMSA-N 0.000 description 3
- JRCUFCXYZLPSDZ-ACZMJKKPSA-N Glu-Asp-Ser Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O JRCUFCXYZLPSDZ-ACZMJKKPSA-N 0.000 description 3
- HNVFSTLPVJWIDV-CIUDSAMLSA-N Glu-Glu-Gln Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HNVFSTLPVJWIDV-CIUDSAMLSA-N 0.000 description 3
- IOUQWHIEQYQVFD-JYJNAYRXSA-N Glu-Leu-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IOUQWHIEQYQVFD-JYJNAYRXSA-N 0.000 description 3
- HRBYTAIBKPNZKQ-AVGNSLFASA-N Glu-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O HRBYTAIBKPNZKQ-AVGNSLFASA-N 0.000 description 3
- LKOAAMXDJGEYMS-ZPFDUUQYSA-N Glu-Met-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LKOAAMXDJGEYMS-ZPFDUUQYSA-N 0.000 description 3
- YRMZCZIRHYCNHX-RYUDHWBXSA-N Glu-Phe-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(O)=O YRMZCZIRHYCNHX-RYUDHWBXSA-N 0.000 description 3
- BFEZQZKEPRKKHV-SRVKXCTJSA-N Glu-Pro-Lys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCC(=O)O)N)C(=O)N[C@@H](CCCCN)C(=O)O BFEZQZKEPRKKHV-SRVKXCTJSA-N 0.000 description 3
- ALMBZBOCGSVSAI-ACZMJKKPSA-N Glu-Ser-Asn Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)O)N ALMBZBOCGSVSAI-ACZMJKKPSA-N 0.000 description 3
- MFYLRRCYBBJYPI-JYJNAYRXSA-N Glu-Tyr-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O MFYLRRCYBBJYPI-JYJNAYRXSA-N 0.000 description 3
- ZALGPUWUVHOGAE-GVXVVHGQSA-N Glu-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZALGPUWUVHOGAE-GVXVVHGQSA-N 0.000 description 3
- SOYWRINXUSUWEQ-DLOVCJGASA-N Glu-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCC(O)=O SOYWRINXUSUWEQ-DLOVCJGASA-N 0.000 description 3
- YOBGUCWZPXJHTN-BQBZGAKWSA-N Gly-Ser-Arg Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YOBGUCWZPXJHTN-BQBZGAKWSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- PZAJPILZRFPYJJ-SRVKXCTJSA-N His-Ser-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O PZAJPILZRFPYJJ-SRVKXCTJSA-N 0.000 description 3
- CYHJCEKUMCNDFG-LAEOZQHASA-N Ile-Gln-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)O)N CYHJCEKUMCNDFG-LAEOZQHASA-N 0.000 description 3
- KLBVGHCGHUNHEA-BJDJZHNGSA-N Ile-Leu-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)O)N KLBVGHCGHUNHEA-BJDJZHNGSA-N 0.000 description 3
- UCOCBWDBHCUPQP-DCAQKATOSA-N Leu-Arg-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O UCOCBWDBHCUPQP-DCAQKATOSA-N 0.000 description 3
- MYGQXVYRZMKRDB-SRVKXCTJSA-N Leu-Asp-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN MYGQXVYRZMKRDB-SRVKXCTJSA-N 0.000 description 3
- PVMPDMIKUVNOBD-CIUDSAMLSA-N Leu-Asp-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O PVMPDMIKUVNOBD-CIUDSAMLSA-N 0.000 description 3
- ZTLGVASZOIKNIX-DCAQKATOSA-N Leu-Gln-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ZTLGVASZOIKNIX-DCAQKATOSA-N 0.000 description 3
- VWHGTYCRDRBSFI-ZETCQYMHSA-N Leu-Gly-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)NCC(O)=O VWHGTYCRDRBSFI-ZETCQYMHSA-N 0.000 description 3
- AUNMOHYWTAPQLA-XUXIUFHCSA-N Leu-Met-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O AUNMOHYWTAPQLA-XUXIUFHCSA-N 0.000 description 3
- WMIOEVKKYIMVKI-DCAQKATOSA-N Leu-Pro-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O WMIOEVKKYIMVKI-DCAQKATOSA-N 0.000 description 3
- SBANPBVRHYIMRR-GARJFASQSA-N Leu-Ser-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N SBANPBVRHYIMRR-GARJFASQSA-N 0.000 description 3
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 3
- PNPYKQFJGRFYJE-GUBZILKMSA-N Lys-Ala-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O PNPYKQFJGRFYJE-GUBZILKMSA-N 0.000 description 3
- YKIRNDPUWONXQN-GUBZILKMSA-N Lys-Asn-Gln Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N YKIRNDPUWONXQN-GUBZILKMSA-N 0.000 description 3
- HIIZIQUUHIXUJY-GUBZILKMSA-N Lys-Asp-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HIIZIQUUHIXUJY-GUBZILKMSA-N 0.000 description 3
- PBLLTSKBTAHDNA-KBPBESRZSA-N Lys-Gly-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PBLLTSKBTAHDNA-KBPBESRZSA-N 0.000 description 3
- WQDKIVRHTQYJSN-DCAQKATOSA-N Lys-Ser-Arg Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N WQDKIVRHTQYJSN-DCAQKATOSA-N 0.000 description 3
- IEVXCWPVBYCJRZ-IXOXFDKPSA-N Lys-Thr-His Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 IEVXCWPVBYCJRZ-IXOXFDKPSA-N 0.000 description 3
- DLCAXBGXGOVUCD-PPCPHDFISA-N Lys-Thr-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O DLCAXBGXGOVUCD-PPCPHDFISA-N 0.000 description 3
- CAVRAQIDHUPECU-UVOCVTCTSA-N Lys-Thr-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAVRAQIDHUPECU-UVOCVTCTSA-N 0.000 description 3
- AHZNUGRZHMZGFL-GUBZILKMSA-N Met-Arg-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CCCNC(N)=N AHZNUGRZHMZGFL-GUBZILKMSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- NHCKESBLOMHIIE-IRXDYDNUSA-N Phe-Gly-Phe Chemical compound C([C@H](N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 NHCKESBLOMHIIE-IRXDYDNUSA-N 0.000 description 3
- JDMKQHSHKJHAHR-UHFFFAOYSA-N Phe-Phe-Leu-Tyr Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)CC1=CC=CC=C1 JDMKQHSHKJHAHR-UHFFFAOYSA-N 0.000 description 3
- UNBFGVQVQGXXCK-KKUMJFAQSA-N Phe-Ser-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O UNBFGVQVQGXXCK-KKUMJFAQSA-N 0.000 description 3
- MHNBYYFXWDUGBW-RPTUDFQQSA-N Phe-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)N)O MHNBYYFXWDUGBW-RPTUDFQQSA-N 0.000 description 3
- UPJGUQPLYWTISV-GUBZILKMSA-N Pro-Gln-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O UPJGUQPLYWTISV-GUBZILKMSA-N 0.000 description 3
- XZONQWUEBAFQPO-HJGDQZAQSA-N Pro-Gln-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XZONQWUEBAFQPO-HJGDQZAQSA-N 0.000 description 3
- NXEYSLRNNPWCRN-SRVKXCTJSA-N Pro-Glu-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NXEYSLRNNPWCRN-SRVKXCTJSA-N 0.000 description 3
- KWMUAKQOVYCQJQ-ZPFDUUQYSA-N Pro-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@@H]1CCCN1 KWMUAKQOVYCQJQ-ZPFDUUQYSA-N 0.000 description 3
- HATVCTYBNCNMAA-AVGNSLFASA-N Pro-Leu-Met Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(O)=O HATVCTYBNCNMAA-AVGNSLFASA-N 0.000 description 3
- KBUAPZAZPWNYSW-SRVKXCTJSA-N Pro-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KBUAPZAZPWNYSW-SRVKXCTJSA-N 0.000 description 3
- PRKWBYCXBBSLSK-GUBZILKMSA-N Pro-Ser-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O PRKWBYCXBBSLSK-GUBZILKMSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229940096437 Protein S Drugs 0.000 description 3
- OYEDZGNMSBZCIM-XGEHTFHBSA-N Ser-Arg-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OYEDZGNMSBZCIM-XGEHTFHBSA-N 0.000 description 3
- KNCJWSPMTFFJII-ZLUOBGJFSA-N Ser-Cys-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(O)=O KNCJWSPMTFFJII-ZLUOBGJFSA-N 0.000 description 3
- MOVJSUIKUNCVMG-ZLUOBGJFSA-N Ser-Cys-Ser Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)O)N)O MOVJSUIKUNCVMG-ZLUOBGJFSA-N 0.000 description 3
- HMRAQFJFTOLDKW-GUBZILKMSA-N Ser-His-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O HMRAQFJFTOLDKW-GUBZILKMSA-N 0.000 description 3
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 3
- XUDRHBPSPAPDJP-SRVKXCTJSA-N Ser-Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CO XUDRHBPSPAPDJP-SRVKXCTJSA-N 0.000 description 3
- PCJLFYBAQZQOFE-KATARQTJSA-N Ser-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N)O PCJLFYBAQZQOFE-KATARQTJSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 101710198474 Spike protein Proteins 0.000 description 3
- ASJDFGOPDCVXTG-KATARQTJSA-N Thr-Cys-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O ASJDFGOPDCVXTG-KATARQTJSA-N 0.000 description 3
- XOTBWOCSLMBGMF-SUSMZKCASA-N Thr-Glu-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XOTBWOCSLMBGMF-SUSMZKCASA-N 0.000 description 3
- YJCVECXVYHZOBK-KNZXXDILSA-N Thr-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H]([C@@H](C)O)N YJCVECXVYHZOBK-KNZXXDILSA-N 0.000 description 3
- BEZTUFWTPVOROW-KJEVXHAQSA-N Thr-Tyr-Arg Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N)O BEZTUFWTPVOROW-KJEVXHAQSA-N 0.000 description 3
- FYBFTPLPAXZBOY-KKHAAJSZSA-N Thr-Val-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O FYBFTPLPAXZBOY-KKHAAJSZSA-N 0.000 description 3
- CTDPLKMBVALCGN-JSGCOSHPSA-N Tyr-Gly-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O CTDPLKMBVALCGN-JSGCOSHPSA-N 0.000 description 3
- PRONOHBTMLNXCZ-BZSNNMDCSA-N Tyr-Leu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PRONOHBTMLNXCZ-BZSNNMDCSA-N 0.000 description 3
- IGXLNVIYDYONFB-UFYCRDLUSA-N Tyr-Phe-Arg Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C1=CC=C(O)C=C1 IGXLNVIYDYONFB-UFYCRDLUSA-N 0.000 description 3
- SYFHQHYTNCQCCN-MELADBBJSA-N Tyr-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O SYFHQHYTNCQCCN-MELADBBJSA-N 0.000 description 3
- PAPWZOJOLKZEFR-AVGNSLFASA-N Val-Arg-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)N PAPWZOJOLKZEFR-AVGNSLFASA-N 0.000 description 3
- SCBITHMBEJNRHC-LSJOCFKGSA-N Val-Asp-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)O)N SCBITHMBEJNRHC-LSJOCFKGSA-N 0.000 description 3
- RKIGNDAHUOOIMJ-BQFCYCMXSA-N Val-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)C(C)C)C(O)=O)=CNC2=C1 RKIGNDAHUOOIMJ-BQFCYCMXSA-N 0.000 description 3
- XXROXFHCMVXETG-UWVGGRQHSA-N Val-Gly-Val Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O XXROXFHCMVXETG-UWVGGRQHSA-N 0.000 description 3
- VHIZXDZMTDVFGX-DCAQKATOSA-N Val-Ser-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N VHIZXDZMTDVFGX-DCAQKATOSA-N 0.000 description 3
- LLJLBRRXKZTTRD-GUBZILKMSA-N Val-Val-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)O)N LLJLBRRXKZTTRD-GUBZILKMSA-N 0.000 description 3
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 description 3
- 108010068380 arginylarginine Proteins 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 108010013768 glutamyl-aspartyl-proline Proteins 0.000 description 3
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 3
- 108010050848 glycylleucine Proteins 0.000 description 3
- 108010015792 glycyllysine Proteins 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 3
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 3
- 108010057821 leucylproline Proteins 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 108010003700 lysyl aspartic acid Proteins 0.000 description 3
- 108010064235 lysylglycine Proteins 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000007923 nasal drop Substances 0.000 description 3
- 229940100662 nasal drops Drugs 0.000 description 3
- 239000006199 nebulizer Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 108010082795 phenylalanyl-arginyl-arginine Proteins 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 108010053725 prolylvaline Proteins 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 108010048397 seryl-lysyl-leucine Proteins 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- IBIDRSSEHFLGSD-UHFFFAOYSA-N valinyl-arginine Natural products CC(C)C(N)C(=O)NC(C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-UHFFFAOYSA-N 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- IPZQNYYAYVRKKK-FXQIFTODSA-N Ala-Pro-Ala Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O IPZQNYYAYVRKKK-FXQIFTODSA-N 0.000 description 2
- PEEYDECOOVQKRZ-DLOVCJGASA-N Ala-Ser-Phe Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PEEYDECOOVQKRZ-DLOVCJGASA-N 0.000 description 2
- SFPRJVVDZNLUTG-OWLDWWDNSA-N Ala-Trp-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SFPRJVVDZNLUTG-OWLDWWDNSA-N 0.000 description 2
- JSHVMZANPXCDTL-GMOBBJLQSA-N Arg-Asp-Ile Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JSHVMZANPXCDTL-GMOBBJLQSA-N 0.000 description 2
- GXXWTNKNFFKTJB-NAKRPEOUSA-N Arg-Ile-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O GXXWTNKNFFKTJB-NAKRPEOUSA-N 0.000 description 2
- LLQIAIUAKGNOSE-NHCYSSNCSA-N Arg-Val-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N LLQIAIUAKGNOSE-NHCYSSNCSA-N 0.000 description 2
- DQTIWTULBGLJBL-DCAQKATOSA-N Asn-Arg-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)N)N DQTIWTULBGLJBL-DCAQKATOSA-N 0.000 description 2
- BVLIJXXSXBUGEC-SRVKXCTJSA-N Asn-Asn-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BVLIJXXSXBUGEC-SRVKXCTJSA-N 0.000 description 2
- WQLJRNRLHWJIRW-KKUMJFAQSA-N Asn-His-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC(=O)N)N)O WQLJRNRLHWJIRW-KKUMJFAQSA-N 0.000 description 2
- UHGUKCOQUNPSKK-CIUDSAMLSA-N Asn-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)N)N UHGUKCOQUNPSKK-CIUDSAMLSA-N 0.000 description 2
- NCFJQJRLQJEECD-NHCYSSNCSA-N Asn-Leu-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O NCFJQJRLQJEECD-NHCYSSNCSA-N 0.000 description 2
- RCFGLXMZDYNRSC-CIUDSAMLSA-N Asn-Lys-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O RCFGLXMZDYNRSC-CIUDSAMLSA-N 0.000 description 2
- REQUGIWGOGSOEZ-ZLUOBGJFSA-N Asn-Ser-Asn Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)C(=O)N REQUGIWGOGSOEZ-ZLUOBGJFSA-N 0.000 description 2
- DATSKXOXPUAOLK-KKUMJFAQSA-N Asn-Tyr-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O DATSKXOXPUAOLK-KKUMJFAQSA-N 0.000 description 2
- KBQOUDLMWYWXNP-YDHLFZDLSA-N Asn-Val-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CC(=O)N)N KBQOUDLMWYWXNP-YDHLFZDLSA-N 0.000 description 2
- YDJVIBMKAMQPPP-LAEOZQHASA-N Asp-Glu-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O YDJVIBMKAMQPPP-LAEOZQHASA-N 0.000 description 2
- AITKTFCQOBRJTG-CIUDSAMLSA-N Asp-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)O)N AITKTFCQOBRJTG-CIUDSAMLSA-N 0.000 description 2
- ZQFRDAZBTSFGGW-SRVKXCTJSA-N Asp-Ser-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O ZQFRDAZBTSFGGW-SRVKXCTJSA-N 0.000 description 2
- NJLLRXWFPQQPHV-SRVKXCTJSA-N Asp-Tyr-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O NJLLRXWFPQQPHV-SRVKXCTJSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- SMEYEQDCCBHTEF-FXQIFTODSA-N Cys-Pro-Ala Chemical compound [H]N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O SMEYEQDCCBHTEF-FXQIFTODSA-N 0.000 description 2
- KSMSFCBQBQPFAD-GUBZILKMSA-N Cys-Pro-Pro Chemical compound SC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 KSMSFCBQBQPFAD-GUBZILKMSA-N 0.000 description 2
- BOMGEMDZTNZESV-QWRGUYRKSA-N Cys-Tyr-Gly Chemical compound SC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=C(O)C=C1 BOMGEMDZTNZESV-QWRGUYRKSA-N 0.000 description 2
- ALTQTAKGRFLRLR-GUBZILKMSA-N Cys-Val-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CS)N ALTQTAKGRFLRLR-GUBZILKMSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000792859 Enema Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- NVEASDQHBRZPSU-BQBZGAKWSA-N Gln-Gln-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O NVEASDQHBRZPSU-BQBZGAKWSA-N 0.000 description 2
- HMIXCETWRYDVMO-GUBZILKMSA-N Gln-Pro-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O HMIXCETWRYDVMO-GUBZILKMSA-N 0.000 description 2
- ININBLZFFVOQIO-JHEQGTHGSA-N Gln-Thr-Gly Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N)O ININBLZFFVOQIO-JHEQGTHGSA-N 0.000 description 2
- DIXKFOPPGWKZLY-CIUDSAMLSA-N Glu-Arg-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O DIXKFOPPGWKZLY-CIUDSAMLSA-N 0.000 description 2
- NJCALAAIGREHDR-WDCWCFNPSA-N Glu-Leu-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NJCALAAIGREHDR-WDCWCFNPSA-N 0.000 description 2
- AAJHGGDRKHYSDH-GUBZILKMSA-N Glu-Pro-Gln Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCC(=O)O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O AAJHGGDRKHYSDH-GUBZILKMSA-N 0.000 description 2
- SYAYROHMAIHWFB-KBIXCLLPSA-N Glu-Ser-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O SYAYROHMAIHWFB-KBIXCLLPSA-N 0.000 description 2
- FVGOGEGGQLNZGH-DZKIICNBSA-N Glu-Val-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FVGOGEGGQLNZGH-DZKIICNBSA-N 0.000 description 2
- WGYHAAXZWPEBDQ-IFFSRLJSSA-N Glu-Val-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WGYHAAXZWPEBDQ-IFFSRLJSSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- LURCIJSJAKFCRO-QWRGUYRKSA-N Gly-Asn-Tyr Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O LURCIJSJAKFCRO-QWRGUYRKSA-N 0.000 description 2
- QSTLUOIOYLYLLF-WDSKDSINSA-N Gly-Asp-Glu Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O QSTLUOIOYLYLLF-WDSKDSINSA-N 0.000 description 2
- PEZZSFLFXXFUQD-XPUUQOCRSA-N Gly-Cys-Val Chemical compound [H]NCC(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O PEZZSFLFXXFUQD-XPUUQOCRSA-N 0.000 description 2
- KMSGYZQRXPUKGI-BYPYZUCNSA-N Gly-Gly-Asn Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC(N)=O KMSGYZQRXPUKGI-BYPYZUCNSA-N 0.000 description 2
- MTBIKIMYHUWBRX-QWRGUYRKSA-N Gly-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN MTBIKIMYHUWBRX-QWRGUYRKSA-N 0.000 description 2
- GAAHQHNCMIAYEX-UWVGGRQHSA-N Gly-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN GAAHQHNCMIAYEX-UWVGGRQHSA-N 0.000 description 2
- JSLVAHYTAJJEQH-QWRGUYRKSA-N Gly-Ser-Phe Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JSLVAHYTAJJEQH-QWRGUYRKSA-N 0.000 description 2
- NWOSHVVPKDQKKT-RYUDHWBXSA-N Gly-Tyr-Gln Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O NWOSHVVPKDQKKT-RYUDHWBXSA-N 0.000 description 2
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 2
- 244000309467 Human Coronavirus Species 0.000 description 2
- VSZALHITQINTGC-GHCJXIJMSA-N Ile-Ala-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)O)N VSZALHITQINTGC-GHCJXIJMSA-N 0.000 description 2
- WZPIKDWQVRTATP-SYWGBEHUSA-N Ile-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)[C@@H](C)CC)C(O)=O)=CNC2=C1 WZPIKDWQVRTATP-SYWGBEHUSA-N 0.000 description 2
- QLRMMMQNCWBNPQ-QXEWZRGKSA-N Ile-Arg-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)O)N QLRMMMQNCWBNPQ-QXEWZRGKSA-N 0.000 description 2
- RQJUKVXWAKJDBW-SVSWQMSJSA-N Ile-Ser-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N RQJUKVXWAKJDBW-SVSWQMSJSA-N 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 2
- 101710192051 Interferon alpha-1/13 Proteins 0.000 description 2
- HUEBCHPSXSQUGN-GARJFASQSA-N Leu-Cys-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)N1CCC[C@@H]1C(=O)O)N HUEBCHPSXSQUGN-GARJFASQSA-N 0.000 description 2
- PBGDOSARRIJMEV-DLOVCJGASA-N Leu-His-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(O)=O PBGDOSARRIJMEV-DLOVCJGASA-N 0.000 description 2
- BKTXKJMNTSMJDQ-AVGNSLFASA-N Leu-His-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N BKTXKJMNTSMJDQ-AVGNSLFASA-N 0.000 description 2
- ZRHDPZAAWLXXIR-SRVKXCTJSA-N Leu-Lys-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O ZRHDPZAAWLXXIR-SRVKXCTJSA-N 0.000 description 2
- UHNQRAFSEBGZFZ-YESZJQIVSA-N Leu-Phe-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N UHNQRAFSEBGZFZ-YESZJQIVSA-N 0.000 description 2
- DPURXCQCHSQPAN-AVGNSLFASA-N Leu-Pro-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DPURXCQCHSQPAN-AVGNSLFASA-N 0.000 description 2
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 2
- UCRJTSIIAYHOHE-ULQDDVLXSA-N Leu-Tyr-Arg Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N UCRJTSIIAYHOHE-ULQDDVLXSA-N 0.000 description 2
- WUHBLPVELFTPQK-KKUMJFAQSA-N Leu-Tyr-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O WUHBLPVELFTPQK-KKUMJFAQSA-N 0.000 description 2
- YQFZRHYZLARWDY-IHRRRGAJSA-N Leu-Val-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN YQFZRHYZLARWDY-IHRRRGAJSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- WSXTWLJHTLRFLW-SRVKXCTJSA-N Lys-Ala-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O WSXTWLJHTLRFLW-SRVKXCTJSA-N 0.000 description 2
- VHNOAIFVYUQOOY-XUXIUFHCSA-N Lys-Arg-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VHNOAIFVYUQOOY-XUXIUFHCSA-N 0.000 description 2
- GCMWRRQAKQXDED-IUCAKERBSA-N Lys-Glu-Gly Chemical compound [NH3+]CCCC[C@H]([NH3+])C(=O)N[C@@H](CCC([O-])=O)C(=O)NCC([O-])=O GCMWRRQAKQXDED-IUCAKERBSA-N 0.000 description 2
- NJNRBRKHOWSGMN-SRVKXCTJSA-N Lys-Leu-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O NJNRBRKHOWSGMN-SRVKXCTJSA-N 0.000 description 2
- ODTZHNZPINULEU-KKUMJFAQSA-N Lys-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N ODTZHNZPINULEU-KKUMJFAQSA-N 0.000 description 2
- AFLBTVGQCQLOFJ-AVGNSLFASA-N Lys-Pro-Arg Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O AFLBTVGQCQLOFJ-AVGNSLFASA-N 0.000 description 2
- LECIJRIRMVOFMH-ULQDDVLXSA-N Lys-Pro-Phe Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 LECIJRIRMVOFMH-ULQDDVLXSA-N 0.000 description 2
- MIFFFXHMAHFACR-KATARQTJSA-N Lys-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCCN MIFFFXHMAHFACR-KATARQTJSA-N 0.000 description 2
- GILLQRYAWOMHED-DCAQKATOSA-N Lys-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN GILLQRYAWOMHED-DCAQKATOSA-N 0.000 description 2
- 101710085938 Matrix protein Proteins 0.000 description 2
- 101710127721 Membrane protein Proteins 0.000 description 2
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 2
- 229920000715 Mucilage Polymers 0.000 description 2
- XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 description 2
- AUEJLPRZGVVDNU-UHFFFAOYSA-N N-L-tyrosyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-UHFFFAOYSA-N 0.000 description 2
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 101150001779 ORF1a gene Proteins 0.000 description 2
- IDUCUXTUHHIQIP-SOUVJXGZSA-N Phe-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O IDUCUXTUHHIQIP-SOUVJXGZSA-N 0.000 description 2
- KJJROSNFBRWPHS-JYJNAYRXSA-N Phe-Glu-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O KJJROSNFBRWPHS-JYJNAYRXSA-N 0.000 description 2
- ZLGQEBCCANLYRA-RYUDHWBXSA-N Phe-Gly-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O ZLGQEBCCANLYRA-RYUDHWBXSA-N 0.000 description 2
- CJAHQEZWDZNSJO-KKUMJFAQSA-N Phe-Lys-Cys Chemical compound NCCCC[C@@H](C(=O)N[C@@H](CS)C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 CJAHQEZWDZNSJO-KKUMJFAQSA-N 0.000 description 2
- IAOZOFPONWDXNT-IXOXFDKPSA-N Phe-Ser-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IAOZOFPONWDXNT-IXOXFDKPSA-N 0.000 description 2
- CDHURCQGUDNBMA-UBHSHLNASA-N Phe-Val-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 CDHURCQGUDNBMA-UBHSHLNASA-N 0.000 description 2
- HFZNNDWPHBRNPV-KZVJFYERSA-N Pro-Ala-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O HFZNNDWPHBRNPV-KZVJFYERSA-N 0.000 description 2
- LUGOKRWYNMDGTD-FXQIFTODSA-N Pro-Cys-Asn Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)O LUGOKRWYNMDGTD-FXQIFTODSA-N 0.000 description 2
- DWGFLKQSGRUQTI-IHRRRGAJSA-N Pro-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1 DWGFLKQSGRUQTI-IHRRRGAJSA-N 0.000 description 2
- ULWBBFKQBDNGOY-RWMBFGLXSA-N Pro-Lys-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@@H]2C(=O)O ULWBBFKQBDNGOY-RWMBFGLXSA-N 0.000 description 2
- JIWJRKNYLSHONY-KKUMJFAQSA-N Pro-Phe-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O JIWJRKNYLSHONY-KKUMJFAQSA-N 0.000 description 2
- AJBQTGZIZQXBLT-STQMWFEESA-N Pro-Phe-Gly Chemical compound C([C@@H](C(=O)NCC(=O)O)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 AJBQTGZIZQXBLT-STQMWFEESA-N 0.000 description 2
- IURWWZYKYPEANQ-HJGDQZAQSA-N Pro-Thr-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O IURWWZYKYPEANQ-HJGDQZAQSA-N 0.000 description 2
- ZYJMLBCDFPIGNL-JYJNAYRXSA-N Pro-Tyr-Arg Chemical compound NC(=N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CCCN1)C(O)=O ZYJMLBCDFPIGNL-JYJNAYRXSA-N 0.000 description 2
- 108091008109 Pseudogenes Proteins 0.000 description 2
- 102000057361 Pseudogenes Human genes 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- UEJYSALTSUZXFV-SRVKXCTJSA-N Rigin Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O UEJYSALTSUZXFV-SRVKXCTJSA-N 0.000 description 2
- 241000315672 SARS coronavirus Species 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- WTUJZHKANPDPIN-CIUDSAMLSA-N Ser-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N WTUJZHKANPDPIN-CIUDSAMLSA-N 0.000 description 2
- YQHZVYJAGWMHES-ZLUOBGJFSA-N Ser-Ala-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YQHZVYJAGWMHES-ZLUOBGJFSA-N 0.000 description 2
- QEDMOZUJTGEIBF-FXQIFTODSA-N Ser-Arg-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O QEDMOZUJTGEIBF-FXQIFTODSA-N 0.000 description 2
- HBOABDXGTMMDSE-GUBZILKMSA-N Ser-Arg-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O HBOABDXGTMMDSE-GUBZILKMSA-N 0.000 description 2
- DOSZISJPMCYEHT-NAKRPEOUSA-N Ser-Ile-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O DOSZISJPMCYEHT-NAKRPEOUSA-N 0.000 description 2
- QMCDMHWAKMUGJE-IHRRRGAJSA-N Ser-Phe-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O QMCDMHWAKMUGJE-IHRRRGAJSA-N 0.000 description 2
- FLONGDPORFIVQW-XGEHTFHBSA-N Ser-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO FLONGDPORFIVQW-XGEHTFHBSA-N 0.000 description 2
- KKKVOZNCLALMPV-XKBZYTNZSA-N Ser-Thr-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O KKKVOZNCLALMPV-XKBZYTNZSA-N 0.000 description 2
- FHXGMDRKJHKLKW-QWRGUYRKSA-N Ser-Tyr-Gly Chemical compound OC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=C(O)C=C1 FHXGMDRKJHKLKW-QWRGUYRKSA-N 0.000 description 2
- YEDSOSIKVUMIJE-DCAQKATOSA-N Ser-Val-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O YEDSOSIKVUMIJE-DCAQKATOSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- LAFLAXHTDVNVEL-WDCWCFNPSA-N Thr-Gln-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N)O LAFLAXHTDVNVEL-WDCWCFNPSA-N 0.000 description 2
- WYKJENSCCRJLRC-ZDLURKLDSA-N Thr-Gly-Cys Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CS)C(=O)O)N)O WYKJENSCCRJLRC-ZDLURKLDSA-N 0.000 description 2
- SPVHQURZJCUDQC-VOAKCMCISA-N Thr-Lys-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O SPVHQURZJCUDQC-VOAKCMCISA-N 0.000 description 2
- VGYVVSQFSSKZRJ-OEAJRASXSA-N Thr-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@H](O)C)CC1=CC=CC=C1 VGYVVSQFSSKZRJ-OEAJRASXSA-N 0.000 description 2
- DNCUODYZAMHLCV-XGEHTFHBSA-N Thr-Pro-Cys Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)O)N)O DNCUODYZAMHLCV-XGEHTFHBSA-N 0.000 description 2
- AXEJRUGTOJPZKG-XGEHTFHBSA-N Thr-Val-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)O)N)O AXEJRUGTOJPZKG-XGEHTFHBSA-N 0.000 description 2
- IBBBOLAPFHRDHW-BPUTZDHNSA-N Trp-Asn-Arg Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N IBBBOLAPFHRDHW-BPUTZDHNSA-N 0.000 description 2
- UKINEYBQXPMOJO-UBHSHLNASA-N Trp-Asn-Ser Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N UKINEYBQXPMOJO-UBHSHLNASA-N 0.000 description 2
- SSSDKJMQMZTMJP-BVSLBCMMSA-N Trp-Tyr-Val Chemical compound C([C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CC=C(O)C=C1 SSSDKJMQMZTMJP-BVSLBCMMSA-N 0.000 description 2
- FBVGQXJIXFZKSQ-GMVOTWDCSA-N Tyr-Ala-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N FBVGQXJIXFZKSQ-GMVOTWDCSA-N 0.000 description 2
- ADBDQGBDNUTRDB-ULQDDVLXSA-N Tyr-Arg-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O ADBDQGBDNUTRDB-ULQDDVLXSA-N 0.000 description 2
- NOOMDULIORCDNF-IRXDYDNUSA-N Tyr-Gly-Phe Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O NOOMDULIORCDNF-IRXDYDNUSA-N 0.000 description 2
- YYLHVUCSTXXKBS-IHRRRGAJSA-N Tyr-Pro-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O YYLHVUCSTXXKBS-IHRRRGAJSA-N 0.000 description 2
- FPCIBLUVDNXPJO-XPUUQOCRSA-N Val-Cys-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CS)C(=O)NCC(O)=O FPCIBLUVDNXPJO-XPUUQOCRSA-N 0.000 description 2
- CPGJELLYDQEDRK-NAKRPEOUSA-N Val-Ile-Ala Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](C)C(O)=O CPGJELLYDQEDRK-NAKRPEOUSA-N 0.000 description 2
- KDKLLPMFFGYQJD-CYDGBPFRSA-N Val-Ile-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](C(C)C)N KDKLLPMFFGYQJD-CYDGBPFRSA-N 0.000 description 2
- BTWMICVCQLKKNR-DCAQKATOSA-N Val-Leu-Ser Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C([O-])=O BTWMICVCQLKKNR-DCAQKATOSA-N 0.000 description 2
- NZGOVKLVQNOEKP-YDHLFZDLSA-N Val-Phe-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(=O)N)C(=O)O)N NZGOVKLVQNOEKP-YDHLFZDLSA-N 0.000 description 2
- GBIUHAYJGWVNLN-AEJSXWLSSA-N Val-Ser-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N GBIUHAYJGWVNLN-AEJSXWLSSA-N 0.000 description 2
- GBIUHAYJGWVNLN-UHFFFAOYSA-N Val-Ser-Pro Natural products CC(C)C(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O GBIUHAYJGWVNLN-UHFFFAOYSA-N 0.000 description 2
- BGTDGENDNWGMDQ-KJEVXHAQSA-N Val-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C(C)C)N)O BGTDGENDNWGMDQ-KJEVXHAQSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 108010041407 alanylaspartic acid Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 108010062796 arginyllysine Proteins 0.000 description 2
- 108010038633 aspartylglutamate Proteins 0.000 description 2
- 239000012911 assay medium Substances 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 108010016616 cysteinylglycine Proteins 0.000 description 2
- 108010060199 cysteinylproline Proteins 0.000 description 2
- 108010069495 cysteinyltyrosine Proteins 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000007920 enema Substances 0.000 description 2
- 229940079360 enema for constipation Drugs 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 2
- 108010074027 glycyl-seryl-phenylalanine Proteins 0.000 description 2
- 108010081551 glycylphenylalanine Proteins 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000010902 jet-milling Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 108010034529 leucyl-lysine Proteins 0.000 description 2
- 108010090333 leucyl-lysyl-proline Proteins 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 108010054155 lysyllysine Proteins 0.000 description 2
- 108010038320 lysylphenylalanine Proteins 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 108010084572 phenylalanyl-valine Proteins 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 108010077112 prolyl-proline Proteins 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 108010078580 tyrosylleucine Proteins 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 108010073969 valyllysine Proteins 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- IESDGNYHXIOKRW-YXMSTPNBSA-N (2s)-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-YXMSTPNBSA-N 0.000 description 1
- DIBLBAURNYJYBF-XLXZRNDBSA-N (2s)-2-[[(2s)-2-[[2-[[(2s)-6-amino-2-[[(2s)-2-amino-3-methylbutanoyl]amino]hexanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@H](NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 DIBLBAURNYJYBF-XLXZRNDBSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 101800000504 3C-like protease Proteins 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 101000621943 Acholeplasma phage L2 Probable integrase/recombinase Proteins 0.000 description 1
- 101000768957 Acholeplasma phage L2 Uncharacterized 37.2 kDa protein Proteins 0.000 description 1
- 101000823746 Acidianus ambivalens Uncharacterized 17.7 kDa protein in bps2 3'region Proteins 0.000 description 1
- 101000916369 Acidianus ambivalens Uncharacterized protein in sor 5'region Proteins 0.000 description 1
- 101000769342 Acinetobacter guillouiae Uncharacterized protein in rpoN-murA intergenic region Proteins 0.000 description 1
- 101000823696 Actinobacillus pleuropneumoniae Uncharacterized glycosyltransferase in aroQ 3'region Proteins 0.000 description 1
- 101000786513 Agrobacterium tumefaciens (strain 15955) Uncharacterized protein outside the virF region Proteins 0.000 description 1
- 101000618005 Alkalihalobacillus pseudofirmus (strain ATCC BAA-2126 / JCM 17055 / OF4) Uncharacterized protein BpOF4_00885 Proteins 0.000 description 1
- 101000618348 Allochromatium vinosum (strain ATCC 17899 / DSM 180 / NBRC 103801 / NCIMB 10441 / D) Uncharacterized protein Alvin_0065 Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 1
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- 102100020724 Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Human genes 0.000 description 1
- HPSVTWMFWCHKFN-GARJFASQSA-N Arg-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O HPSVTWMFWCHKFN-GARJFASQSA-N 0.000 description 1
- NKLRWRRVYGQNIH-GHCJXIJMSA-N Asn-Ile-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O NKLRWRRVYGQNIH-GHCJXIJMSA-N 0.000 description 1
- LGCVSPFCFXWUEY-IHPCNDPISA-N Asn-Trp-Tyr Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N LGCVSPFCFXWUEY-IHPCNDPISA-N 0.000 description 1
- PDECQIHABNQRHN-GUBZILKMSA-N Asp-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O PDECQIHABNQRHN-GUBZILKMSA-N 0.000 description 1
- SNDBKTFJWVEVPO-WHFBIAKZSA-N Asp-Gly-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(O)=O SNDBKTFJWVEVPO-WHFBIAKZSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003757 Atypical pneumonia Diseases 0.000 description 1
- 101000781117 Autographa californica nuclear polyhedrosis virus Uncharacterized 12.4 kDa protein in CTL-LEF2 intergenic region Proteins 0.000 description 1
- 101000967489 Azorhizobium caulinodans (strain ATCC 43989 / DSM 5975 / JCM 20966 / LMG 6465 / NBRC 14845 / NCIMB 13405 / ORS 571) Uncharacterized protein AZC_3924 Proteins 0.000 description 1
- 101000708323 Azospirillum brasilense Uncharacterized 28.8 kDa protein in nifR3-like 5'region Proteins 0.000 description 1
- 101000770311 Azotobacter chroococcum mcd 1 Uncharacterized 19.8 kDa protein in nifW 5'region Proteins 0.000 description 1
- 101000823761 Bacillus licheniformis Uncharacterized 9.4 kDa protein in flaL 3'region Proteins 0.000 description 1
- 101000819719 Bacillus methanolicus Uncharacterized N-acetyltransferase in lysA 3'region Proteins 0.000 description 1
- 101000789586 Bacillus subtilis (strain 168) UPF0702 transmembrane protein YkjA Proteins 0.000 description 1
- 101000748761 Bacillus subtilis (strain 168) Uncharacterized MFS-type transporter YcxA Proteins 0.000 description 1
- 101000792624 Bacillus subtilis (strain 168) Uncharacterized protein YbxH Proteins 0.000 description 1
- 101000790792 Bacillus subtilis (strain 168) Uncharacterized protein YckC Proteins 0.000 description 1
- 101000765620 Bacillus subtilis (strain 168) Uncharacterized protein YlxP Proteins 0.000 description 1
- 101000819705 Bacillus subtilis (strain 168) Uncharacterized protein YlxR Proteins 0.000 description 1
- 101000916134 Bacillus subtilis (strain 168) Uncharacterized protein YqxJ Proteins 0.000 description 1
- 101000948218 Bacillus subtilis (strain 168) Uncharacterized protein YtxJ Proteins 0.000 description 1
- 101000718627 Bacillus thuringiensis subsp. kurstaki Putative RNA polymerase sigma-G factor Proteins 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 101000641200 Bombyx mori densovirus Putative non-structural protein Proteins 0.000 description 1
- 101000754349 Bordetella pertussis (strain Tohama I / ATCC BAA-589 / NCTC 13251) UPF0065 protein BP0148 Proteins 0.000 description 1
- 101000827633 Caldicellulosiruptor sp. (strain Rt8B.4) Uncharacterized 23.9 kDa protein in xynA 3'region Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 101000947628 Claviceps purpurea Uncharacterized 11.8 kDa protein Proteins 0.000 description 1
- 101000947633 Claviceps purpurea Uncharacterized 13.8 kDa protein Proteins 0.000 description 1
- 101000686796 Clostridium perfringens Replication protein Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- ZXCAQANTQWBICD-DCAQKATOSA-N Cys-Lys-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N ZXCAQANTQWBICD-DCAQKATOSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 101000948901 Enterobacteria phage T4 Uncharacterized 16.0 kDa protein in segB-ipI intergenic region Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 101710204837 Envelope small membrane protein Proteins 0.000 description 1
- 101000805958 Equine herpesvirus 4 (strain 1942) Virion protein US10 homolog Proteins 0.000 description 1
- 101000790442 Escherichia coli Insertion element IS2 uncharacterized 11.1 kDa protein Proteins 0.000 description 1
- 101000788129 Escherichia coli Uncharacterized protein in sul1 3'region Proteins 0.000 description 1
- 101000788370 Escherichia phage P2 Uncharacterized 12.9 kDa protein in GpA 3'region Proteins 0.000 description 1
- 101000788354 Escherichia phage P2 Uncharacterized 8.2 kDa protein in gpA 5'region Proteins 0.000 description 1
- 101000770304 Frankia alni UPF0460 protein in nifX-nifW intergenic region Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 101000797344 Geobacillus stearothermophilus Putative tRNA (cytidine(34)-2'-O)-methyltransferase Proteins 0.000 description 1
- 101000748410 Geobacillus stearothermophilus Uncharacterized protein in fumA 3'region Proteins 0.000 description 1
- 101000787096 Geobacillus stearothermophilus Uncharacterized protein in gldA 3'region Proteins 0.000 description 1
- CSMHMEATMDCQNY-DZKIICNBSA-N Gln-Val-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CSMHMEATMDCQNY-DZKIICNBSA-N 0.000 description 1
- GLWXKFRTOHKGIT-ACZMJKKPSA-N Glu-Asn-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O GLWXKFRTOHKGIT-ACZMJKKPSA-N 0.000 description 1
- ZWQVYZXPYSYPJD-RYUDHWBXSA-N Glu-Gly-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZWQVYZXPYSYPJD-RYUDHWBXSA-N 0.000 description 1
- GRIRDMVMJJDZKV-RCOVLWMOSA-N Gly-Asn-Val Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O GRIRDMVMJJDZKV-RCOVLWMOSA-N 0.000 description 1
- PABFFPWEJMEVEC-JGVFFNPUSA-N Gly-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)CN)C(=O)O PABFFPWEJMEVEC-JGVFFNPUSA-N 0.000 description 1
- SYOJVRNQCXYEOV-XVKPBYJWSA-N Gly-Val-Glu Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SYOJVRNQCXYEOV-XVKPBYJWSA-N 0.000 description 1
- FNXSYBOHALPRHV-ONGXEEELSA-N Gly-Val-Lys Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN FNXSYBOHALPRHV-ONGXEEELSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000772675 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) UPF0438 protein HI_0847 Proteins 0.000 description 1
- 101000631019 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Uncharacterized protein HI_0350 Proteins 0.000 description 1
- 101000976889 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 19.2 kDa protein in cox-rep intergenic region Proteins 0.000 description 1
- 101000768938 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 8.9 kDa protein in int-C1 intergenic region Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- WMKXFMUJRCEGRP-SRVKXCTJSA-N His-Asn-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N WMKXFMUJRCEGRP-SRVKXCTJSA-N 0.000 description 1
- 101000785414 Homo sapiens Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Proteins 0.000 description 1
- 101001034829 Homo sapiens Interferon alpha-10 Proteins 0.000 description 1
- 101001034828 Homo sapiens Interferon alpha-14 Proteins 0.000 description 1
- 101001034835 Homo sapiens Interferon alpha-16 Proteins 0.000 description 1
- 101001034834 Homo sapiens Interferon alpha-17 Proteins 0.000 description 1
- 101000959708 Homo sapiens Interferon alpha-4 Proteins 0.000 description 1
- 101000959704 Homo sapiens Interferon alpha-5 Proteins 0.000 description 1
- 101000959714 Homo sapiens Interferon alpha-6 Proteins 0.000 description 1
- 101000961126 Homo sapiens Interferon alpha-7 Proteins 0.000 description 1
- 101000999391 Homo sapiens Interferon alpha-8 Proteins 0.000 description 1
- 101000852870 Homo sapiens Interferon alpha/beta receptor 1 Proteins 0.000 description 1
- 101001001420 Homo sapiens Interferon gamma receptor 1 Proteins 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- 102100039734 Interferon alpha-10 Human genes 0.000 description 1
- 102100039733 Interferon alpha-14 Human genes 0.000 description 1
- 102100039728 Interferon alpha-16 Human genes 0.000 description 1
- 102100039730 Interferon alpha-17 Human genes 0.000 description 1
- 102100039949 Interferon alpha-4 Human genes 0.000 description 1
- 102100039948 Interferon alpha-5 Human genes 0.000 description 1
- 102100040007 Interferon alpha-6 Human genes 0.000 description 1
- 102100039350 Interferon alpha-7 Human genes 0.000 description 1
- 102100036532 Interferon alpha-8 Human genes 0.000 description 1
- 102100036714 Interferon alpha/beta receptor 1 Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102100035678 Interferon gamma receptor 1 Human genes 0.000 description 1
- 102100036157 Interferon gamma receptor 2 Human genes 0.000 description 1
- 102100037971 Interferon lambda receptor 1 Human genes 0.000 description 1
- 101710145151 Interferon lambda receptor 1 Proteins 0.000 description 1
- 102100020989 Interferon lambda-2 Human genes 0.000 description 1
- 101710099622 Interferon lambda-2 Proteins 0.000 description 1
- 102100020992 Interferon lambda-3 Human genes 0.000 description 1
- 101710099621 Interferon lambda-3 Proteins 0.000 description 1
- 102100020788 Interleukin-10 receptor subunit beta Human genes 0.000 description 1
- 101710199214 Interleukin-10 receptor subunit beta Proteins 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 101000782488 Junonia coenia densovirus (isolate pBRJ/1990) Putative non-structural protein NS2 Proteins 0.000 description 1
- 101000827627 Klebsiella pneumoniae Putative low molecular weight protein-tyrosine-phosphatase Proteins 0.000 description 1
- 101000811523 Klebsiella pneumoniae Uncharacterized 55.8 kDa protein in cps region Proteins 0.000 description 1
- 101000818409 Lactococcus lactis subsp. lactis Uncharacterized HTH-type transcriptional regulator in lacX 3'region Proteins 0.000 description 1
- 101000878851 Leptolyngbya boryana Putative Fe(2+) transport protein A Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000034800 Leukoencephalopathies Diseases 0.000 description 1
- XNKDCYABMBBEKN-IUCAKERBSA-N Lys-Gly-Gln Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O XNKDCYABMBBEKN-IUCAKERBSA-N 0.000 description 1
- SLQJJFAVWSZLBL-BJDJZHNGSA-N Lys-Ile-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCCCN SLQJJFAVWSZLBL-BJDJZHNGSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710145006 Lysis protein Proteins 0.000 description 1
- 108050005735 Maltoporin Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 101000758828 Methanosarcina barkeri (strain Fusaro / DSM 804) Uncharacterized protein Mbar_A1602 Proteins 0.000 description 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 1
- 101001122401 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF3 Proteins 0.000 description 1
- 101000982327 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF4a Proteins 0.000 description 1
- 101001130841 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF5 Proteins 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 101001055788 Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) Pentapeptide repeat protein MfpA Proteins 0.000 description 1
- 101710091700 Non-structural protein ORF4b Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 101000740670 Orgyia pseudotsugata multicapsid polyhedrosis virus Protein C42 Proteins 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 108091007493 Papain-like protease two domains Proteins 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- MSHZERMPZKCODG-ACRUOGEOSA-N Phe-Leu-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 MSHZERMPZKCODG-ACRUOGEOSA-N 0.000 description 1
- 101000769182 Photorhabdus luminescens Uncharacterized protein in pnp 3'region Proteins 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- TUYWCHPXKQTISF-LPEHRKFASA-N Pro-Cys-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CS)C(=O)N2CCC[C@@H]2C(=O)O TUYWCHPXKQTISF-LPEHRKFASA-N 0.000 description 1
- VPEVBAUSTBWQHN-NHCYSSNCSA-N Pro-Glu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O VPEVBAUSTBWQHN-NHCYSSNCSA-N 0.000 description 1
- PCWLNNZTBJTZRN-AVGNSLFASA-N Pro-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 PCWLNNZTBJTZRN-AVGNSLFASA-N 0.000 description 1
- GOMUXSCOIWIJFP-GUBZILKMSA-N Pro-Ser-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GOMUXSCOIWIJFP-GUBZILKMSA-N 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 101000961392 Pseudescherichia vulneris Uncharacterized 29.9 kDa protein in crtE 3'region Proteins 0.000 description 1
- 101000731030 Pseudomonas oleovorans Poly(3-hydroxyalkanoate) polymerase 2 Proteins 0.000 description 1
- 101000933967 Pseudomonas phage KPP25 Major capsid protein Proteins 0.000 description 1
- 101001065485 Pseudomonas putida Probable fatty acid methyltransferase Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 101000711023 Rhizobium leguminosarum bv. trifolii Uncharacterized protein in tfuA 3'region Proteins 0.000 description 1
- 101000974028 Rhizobium leguminosarum bv. viciae (strain 3841) Putative cystathionine beta-lyase Proteins 0.000 description 1
- 101000756519 Rhodobacter capsulatus (strain ATCC BAA-309 / NBRC 16581 / SB1003) Uncharacterized protein RCAP_rcc00048 Proteins 0.000 description 1
- 101000948219 Rhodococcus erythropolis Uncharacterized 11.5 kDa protein in thcD 3'region Proteins 0.000 description 1
- 101000948156 Rhodococcus erythropolis Uncharacterized 47.3 kDa protein in thcA 5'region Proteins 0.000 description 1
- 101000917565 Rhodococcus fascians Uncharacterized 33.6 kDa protein in fasciation locus Proteins 0.000 description 1
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 description 1
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 1
- 101000790284 Saimiriine herpesvirus 2 (strain 488) Uncharacterized 9.5 kDa protein in DHFR 3'region Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- VGNYHOBZJKWRGI-CIUDSAMLSA-N Ser-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO VGNYHOBZJKWRGI-CIUDSAMLSA-N 0.000 description 1
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 1
- GZSZPKSBVAOGIE-CIUDSAMLSA-N Ser-Lys-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O GZSZPKSBVAOGIE-CIUDSAMLSA-N 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 102220590324 Spindlin-1_D80A_mutation Human genes 0.000 description 1
- 102220590628 Spindlin-1_L18F_mutation Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 101000936719 Streptococcus gordonii Accessory Sec system protein Asp3 Proteins 0.000 description 1
- 101000936711 Streptococcus gordonii Accessory secretory protein Asp4 Proteins 0.000 description 1
- 101000929863 Streptomyces cinnamonensis Monensin polyketide synthase putative ketoacyl reductase Proteins 0.000 description 1
- 101000788499 Streptomyces coelicolor Uncharacterized oxidoreductase in mprA 5'region Proteins 0.000 description 1
- 101000788468 Streptomyces coelicolor Uncharacterized protein in mprR 3'region Proteins 0.000 description 1
- 101001102841 Streptomyces griseus Purine nucleoside phosphorylase ORF3 Proteins 0.000 description 1
- 101000708557 Streptomyces lincolnensis Uncharacterized 17.2 kDa protein in melC2-rnhH intergenic region Proteins 0.000 description 1
- 101000845085 Streptomyces violaceoruber Granaticin polyketide synthase putative ketoacyl reductase 1 Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 101000649826 Thermotoga neapolitana Putative anti-sigma factor antagonist TM1081 homolog Proteins 0.000 description 1
- 101000711771 Thiocystis violacea Uncharacterized 76.5 kDa protein in phbC 3'region Proteins 0.000 description 1
- TZKPNGDGUVREEB-FOHZUACHSA-N Thr-Asn-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O TZKPNGDGUVREEB-FOHZUACHSA-N 0.000 description 1
- KWQBJOUOSNJDRR-XAVMHZPKSA-N Thr-Cys-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)N1CCC[C@@H]1C(=O)O)N)O KWQBJOUOSNJDRR-XAVMHZPKSA-N 0.000 description 1
- DSLHSTIUAPKERR-XGEHTFHBSA-N Thr-Cys-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O DSLHSTIUAPKERR-XGEHTFHBSA-N 0.000 description 1
- XFTYVCHLARBHBQ-FOHZUACHSA-N Thr-Gly-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O XFTYVCHLARBHBQ-FOHZUACHSA-N 0.000 description 1
- MPUMPERGHHJGRP-WEDXCCLWSA-N Thr-Gly-Lys Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)N)O MPUMPERGHHJGRP-WEDXCCLWSA-N 0.000 description 1
- NCXVJIQMWSGRHY-KXNHARMFSA-N Thr-Leu-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N)O NCXVJIQMWSGRHY-KXNHARMFSA-N 0.000 description 1
- PELIQFPESHBTMA-WLTAIBSBSA-N Thr-Tyr-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=C(O)C=C1 PELIQFPESHBTMA-WLTAIBSBSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- DQDXHYIEITXNJY-BPUTZDHNSA-N Trp-Gln-Gln Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N DQDXHYIEITXNJY-BPUTZDHNSA-N 0.000 description 1
- RIVVDNTUSRVTQT-IRIUXVKKSA-N Tyr-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O RIVVDNTUSRVTQT-IRIUXVKKSA-N 0.000 description 1
- SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 1
- HPANGHISDXDUQY-ULQDDVLXSA-N Val-Lys-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N HPANGHISDXDUQY-ULQDDVLXSA-N 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- 101000711318 Vibrio alginolyticus Uncharacterized 11.6 kDa protein in scrR 3'region Proteins 0.000 description 1
- 101000827562 Vibrio alginolyticus Uncharacterized protein in proC 3'region Proteins 0.000 description 1
- 101000778915 Vibrio parahaemolyticus serotype O3:K6 (strain RIMD 2210633) Uncharacterized membrane protein VP2115 Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000713325 Visna/maedi virus Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 201000010064 diabetes insipidus Diseases 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108010078144 glutaminyl-glycine Proteins 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 108010085650 interferon gamma receptor Proteins 0.000 description 1
- 239000002799 interferon inducing agent Substances 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 208000002741 leukoplakia Diseases 0.000 description 1
- 229960004873 levomenthol Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 108010070643 prolylglutamic acid Proteins 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 102220033185 rs62646881 Human genes 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 108010052774 valyl-lysyl-glycyl-phenylalanyl-tyrosine Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本公开提供一种新型冠状病毒SARS‑CoV‑2的协同免疫及其用途。所述疫苗是一种疫苗组合产品,其包含:(i)亲本株疫苗和(ii)突变株疫苗。本公开提供了一种联合用药,可使受试者获得更高滴度的中和抗体与更广谱的保护力,可显著提升对新冠病毒及多种突变株病毒的防御能力,达到协同免疫的效果。
Description
技术领域
本公开属于生物技术领域,具体涉及新型冠状病毒SARS-CoV-2的协同免疫及其用途。
背景技术
新型冠状病毒(2019-nCoV,SARS-CoV-2)是一种β属的冠状病毒,于2019年首次被发现,是目前已知的第七种能感染人的冠状病毒,感染该病毒后可导致患者出现发热、干咳、乏力等症状;部分患者会产生严重的肺炎,进而发展为急性呼吸窘迫综合征、脓毒症休克、出凝血功能障碍及多器官功能衰竭等,甚至死亡。冠状病毒是一类具有囊膜、基因组为线性单股正链的RNA病毒,是自然界广泛存在的一大类病毒。最新序列研究分析表明,从临床病人分离的SARS-CoV-2和蝙蝠来源的冠状病毒RaTG13有96%的一致性,和SARS冠状病毒也有79.3%的同一性。冠状基因组结构较为保守,包含11个功能性开放阅读框,依次为ORF1a、ORF1b、S、ORF3、ORF4a、ORF4b、ORF5、E、M、ORF8b和N。其中ORF1a和ORF1b分别编码在所有冠状病毒中均保守的两种复制酶PL2pro和3CLpro。ORF3、4a、4b、5和8b分别编码了病毒的5种附属蛋白。ORFs S、E、M和N编码了的4种主要结构蛋白—刺突蛋白(Spike Protein,S)、包膜蛋白(Envelope Protein,E)、膜蛋白(Membrane Protein,M)和核衣壳蛋白(Nucleocapsid Protein,N)。其中,E蛋白为在病毒表面形成离子通道的一种跨膜蛋白,与病毒毒力相关。N蛋白是病毒基因组RNA复制复合物的主要组成部分,并与M蛋白的C端结构域结合。M蛋白是构成冠状病毒粒子形状的蛋白,参与病毒组分在病毒粒子中的整合。S蛋白突出于病毒粒子表面,为I型跨膜糖蛋白,与病毒颗粒吸附和膜融合相关,根据2006年非典型肺炎的相关研究报道,S蛋白是诱导机体产生中和抗体的主要免疫原,S蛋白在之后成为中东呼吸综合症病毒MERS疫苗和基因工程药物开发的重要靶点。鉴于以往工作经验,S蛋白成为针对SARS-COV-2的首选抗原。
冠状病毒的核酸为非节段单链(+)RNA,长27-31kb,是RNA病毒中最长的RNA核酸链,突变可以说是新冠病毒这类RNA病毒的最大特性。病毒入侵宿主细胞后,会大量复制自己来实现感染传播。在复制过程中,RNA病毒并没有校正机制,出现复制错误无法自行纠正,在大量的复制中就容易出现新的变异,而新的变异的结果是导致疫苗有效性降低或者失效的主要原因。
据世界卫生组织官网显示,目前全世界已经发现数百种新冠病毒的变种,其中“南非”突变株出现于2020年12月,在南非首次发现,因此被命名为“南非”株,现已经在非洲、欧洲、亚洲和澳大利亚发现。相比于野生型病毒株,南非突变株共发生21个突变,8个在刺突Spike蛋白上的突变,例如:L18F、D80A、D215G、R246I、K417N、E484K、N501Y和A701V;还有刺突蛋白以外的ORF1b缺失。目前的研究初步认为传染性增强,致病力是否增强正在研究,体外研究表明,其具有自然感染后免疫逃逸的可能性,并且影响了疫苗的效应。
这些位点是新冠病毒抗体或疫苗产生作用很重要的靶位点。如果这些位点发生变异,会增加抗体对病毒的识别难度,从而使病毒逃避“追杀”;Spike区域发生突变,容易导致“抗体中和逃逸”现象出现,简单来说,南非株的这些突变特性有可能让它变得感染性更强、更容易传播有可能会让它更容易逃脱抗体的追杀,可能导致疫苗失效。
研究证实,大多数中和抗体都针对新型冠状病毒的突刺蛋白(S)的受体结合域(Receptor Binding Domain,RBD),RBD是病毒进入宿主细胞的关键部位,RBD蛋白可以和细胞的ACE2受体相互作用,打开细胞表面通道,使病毒颗粒得以进入细胞内,完成病毒入侵过程,因此研发针对新冠病毒突变株的重组RBD疫苗是有效防治病毒突变株的重点。
新型冠状病毒在不停地突变之中,许多流行的SARS-CoV-2突变体与病例数迅速增加有关,例如英国突变株B.1.1.7/501Y.V1、南非突变株B.1.351/501Y.V2,以及巴西突变株P.1/501Y.V3。上述新冠病毒突变体可以降低疫苗诱导的血浆中和抗体的中和能力。
目前市售/在研新冠疫苗,大多采用野生型S蛋白或RBD设计,对野生型或早期新冠突变株病御能力较好,但对目前流行的变异株(主要为B.1.351/501Y.V2南非突变株)已出现不同程度的保护力下降现象。因此,亟需针对突变型新型冠状病毒的流行,开发出提高新型冠状病毒SARS-CoV-2及其突变株协同免疫效果的联合用药方法。
发明内容
为了避免现有疫苗的局限,本公开提供了一种提高新型冠状病毒SARS-CoV-2及其突变株协同免疫效果的疫苗联合。与已知的灭活、腺病毒以及mRNA新冠病毒疫苗都不同,本公开的突变株疫苗使用的抗原是针对突变新冠毒株的抗原部分(特别是RBD部分),通过变异型RBD增加对突变株的防御能力。用本公开所提供的方法使用这种突变株疫苗可在动物体内、人体内诱导更强的免疫应答。所以,本公开的突变株疫苗,对比传统单一抗原新冠疫苗,具有更高的免疫原性、更强的防御能力。综合以上所有创新设计和优化,本公开的突变株疫苗可作为新一代突变株疫苗药物,用于抵御新冠疫情蔓延。利用本公开所提供的方法使用亲本株疫苗和突变株疫苗可通过调整剂次数量和各剂次所施用的疫苗来提升中和抗体的滴度,保证高效产生中和抗体,可显著提升对突变株的防御能力。
在一方面,本公开提供了一种治疗或预防与SARS-CoV-2相关的疾病或病状的疫苗组合产品,所述疫苗组合产品包含:
(i)亲本株疫苗,所述亲本株疫苗包含野生型SARS-CoV-2多肽的融合蛋白,所述野生型SARS-CoV-2融合蛋白包含:(1)干扰素或其功能片段;(2)野生型SARS-CoV-2的S蛋白的RBD或其功能片段;和(3)免疫球蛋白Fc区;和
(ii)突变株疫苗,所述突变株疫苗包含突变型SARS-CoV-2多肽的融合蛋白,所述突变型SARS-CoV-2融合蛋白包含:(1)干扰素或其功能片段;(2)突变型SARS-CoV-2的S蛋白的RBD或其功能片段;和(3)免疫球蛋白Fc区;
其中,所述亲本株疫苗或所述突变株疫苗中的一种作为引发疫苗施用,所述亲本株疫苗或所述突变株疫苗中的一种作为加强疫苗施用,并且所述亲本株疫苗和所述突变株疫苗两者均被施用。
在另一方面,本公开提供了一种制备所述疫苗组合产品的方法。
在另一方面,本公开提供了一种亲本株疫苗和突变株疫苗在制备治疗或预防与SARS-CoV-2相关的疾病或病状的疫苗组合产品中的用途。
在另一方面,本公开提供了一种在有相应需要的受试者中诱导针对SARS-CoV-2的免疫应答的方法,所述方法包括:
(i)向受试者施用亲本株疫苗;和
(ii)向受试者施用突变株疫苗。
在另一方面,本公开提供了一种编码所述的疫苗组合产品的核酸。
在另一方面,本公开提供了一种包含所述的核酸的表达载体。
在另一方面,本公开提供了一种表达所述的疫苗组合产品、包含所述的核酸和/或包含所述的表达载体的宿主细胞。
在另一方面,本公开提供了一种试剂盒,其包含所述的疫苗组合产品、所述的核酸、所述的表达载体和/或所述的宿主细胞。
在另一方面,本公开提供了一种所述的试剂盒在制备用于在有相应需要的受试者中诱导针对新型冠状病毒SARS-CoV-2的免疫应答的药物组合物中的用途。
附图说明
图1示出了亲本株疫苗与南非株疫苗的不同免疫程序对野生型假病毒的中和效价。
图2示出了亲本株疫苗与南非株疫苗的不同免疫程序对南非株假病毒的中和效价。
图3示出了亲本株疫苗与南非株疫苗的不同免疫程序对野生株假病毒、美国株CAL.20C假病毒、印度株B.1.617.1假病毒和印度株B.1.617.2假病毒的中和效价水平。
图4示出了亲本株疫苗与南非株疫苗的联合注射给药的免疫程序和二价苗注射给药的免疫程序对野生株假病毒的中和效价。
图5示出了亲本株疫苗与南非株疫苗的联合注射给药的免疫程序和二价苗注射给药的免疫程序对南非株假病毒的中和效价。
具体实施方式
I.定义
在本公开中,除非另有说明,否则本文中使用的科学和技术名词具有本领域技术人员所通常理解的含义。并且,本文中所用的蛋白质和核酸化学、分子生物学、细胞和组织培养、微生物学、免疫学相关术语和实验室操作步骤均为相应领域内广泛使用的术语和常规步骤。同时,为了更好地理解本公开,下面提供相关术语的定义和解释。
如本文使用的和除非另作说明,术语“约”或“大约”是指在给定值或范围的加或减10%之内。在需要整数的情况下,该术语是指在给定值或范围的加或减10%之内、向上或向下舍入到最接近的整数。
如本文使用的和除非另作说明,术语“包含”,“包括”,“具有”,“含有”,包括其语法上的等同形式,通常应当理解为开放式且非限制性的,例如,不排除其他未列举的要素或步骤。
如本文所使用的,术语“冠状病毒(Coronavirus)”属于冠状病毒科,冠状病毒属,可以感染哺乳动物和禽类,引起呼吸系统、消化和中枢神经的各种疾病。根据基因组和血清学差异可以将冠状病毒分成四个不同的属:α、β、γ和δ,目前只有α和β属冠状病毒感染人类。截至目前已鉴定出来自两个属(α和β)的6种人冠状病毒(HCoV),α属冠状病毒包括NL63和229E,β属冠状病毒包括OC43、HKU1、急性呼吸系统综合征冠状病毒(SARS-CoV)、中东呼吸综合征冠状病毒(MERS-CoV)和新型冠状肺炎病毒(SARS-CoV-2)。
如本文所使用的,术语“COVID-19”是一种病毒性疾病,通常以高烧、咳嗽、呼吸困难、寒意、持续震颤、肌肉疼痛、头痛、咽喉痛、新的味觉和/或嗅觉丧失和病毒性肺炎的其他症状为特征。在严重的情况下,会出现大量与COVID-19严重程度相关的凝血病相关症状(例如,血液凝固、血栓形成、急性呼吸窘迫综合征、癫痫发作、心脏病发作、中风、多发性脑梗塞、肾衰竭尿崩症和/或弥散性血管内凝血)。在年轻患者中,罕见的炎症综合征有时与COVID-19相关(例如,非典型川崎综合征、中毒性休克综合征、小儿多系统炎性疾病、和细胞因子风暴综合征)。β属的冠状病毒SARS-CoV-2是致病因子(causative agent)。
如本文所使用的,术语“融合蛋白”是指由一种或多种分子组成的天然或合成分子,其中具有不同特异性的两种或多种基于肽或蛋白质(包括糖蛋白)的分子任选的通过化学的或基于氨基酸的接头分子融合在一起。该连接可通过C-N融合或N-C融合(以5′→3′方向),优选C-N融合而实现。
如本文所使用的,术语“干扰素”(Interferon,IFN)指机体受到病毒感染或在其他干扰素诱生剂作用下,由细胞基因组控制产生的具有抗病毒、抗肿瘤和免疫调节活性等多种生物学活性的一类细胞因子。干扰素可以根据它们的生物和物理性质分成三大类:I型、II型和III型干扰素。
I型干扰素构建了在结构上相关的家族(IFN-α(α)、IFN-β(β)、IFN-κ(κ)、IFN-δ(δ)、IFN-ε(ε)、IFN-τ(τ)、IFN-ω(ω)和IFN-ζ(ζ)),其中IFN-δ和IFN-τ不会在人类中出现。人I型干扰素(IFN)基因簇集在人染色体9p21上,而小鼠基因位于小鼠4号染色体上的保守的共线性区中。迄今为止,已在小鼠中鉴定出14种IFN-α基因和3种伪基因。在人类中,已经鉴定出13种IFN-α(或IFNA)基因(IFNA1、IFNA2、IFNA4、IFNA5、IFNA6、IFNA7、IFNA8、IFNA10、IFNA13、IFNA14、IFNA16、IFNA17和IFNA21)以及1个伪基因,其中两种人IFN-α基因(IFNA1/IFN-α1和IFNA13/IFN-α13)针对相同的蛋白编码。所有的人I型干扰素结合至由两种跨膜蛋白(IFNAR-1和IFNAR-2)组成的细胞表面受体(IFNα受体,IFNAR),该细胞表面受体引起JAK-STAT活化、ISGF3的形成和随后开始的基因表达。干扰素γ(IFN-γ)是唯一已知II型干扰素,其主要涉及通过巨噬细胞刺激诱导抗菌和抗肿瘤机制。IFN-γ受体(IFNGR)是由与两种信号转导IFNGR2链相关联的两种配体结合IFNGR1链组成的异质二聚体受体。III型干扰素由三种亚型组成,并且还被称为IFNλ(IFNλ1或IL-29、IFNλ2或IL-28A和IFNλ3或IL-28B),且具有抗病毒、抗肿瘤和免疫调节活性。IFN-λ受体也是由唯一的配体结合链IFN-λR1(也被指定为IL-28Rα)以及与用于IL-10相关细胞因子的受体共享的副链IL-10R2组成的异质二聚体复合物。
如本文所使用的,术语“抗体”或“免疫球蛋白”有最广义的含义,特别包括完整的单克隆抗体、多克隆抗体、由至少2个完整抗体构成的多特异性抗体(例如双特异性抗体)以及抗体片段,只要其显示出具有所需的生物学活性即可。此术语一般包括由2个或多个具有不同结合特异性的抗体或抗体片段连接在一起构成的杂合抗体。
如本文所使用的,术语“Fc区”在本文中用于定义免疫球蛋白重链的C端区,包括天然序列Fc区和变体Fc区。尽管免疫球蛋白重链的Fc区的边界可以变化,但人IgG重链Fc区通常定义为自位置Cys226,或自Pro230处的氨基酸残基延伸至重链的羧基端。可以除去Fc区的C端赖氨酸(依照EU编号系统的残基447),例如在抗体的产生或纯化期间,或通过重组工程化改造编码抗体重链的核酸。因此,完整抗体的组合物可以包含已除去所有K447残基的抗体群体,未除去任何K447残基的抗体群体,和具有有和无K447残基的抗体混合物的抗体群体。
如本文所使用的,序列“相同性”或“同一性”具有本领域公认的含义,并且可以利用公开的技术计算两个核酸或多肽分子或区域之间序列相同性的百分比。可以沿着多核苷酸或多肽的全长或者沿着该分子的区域测量序列相同性。虽然存在许多测量两个多核苷酸或多肽之间的相同性的方法,但是术语“相同性”是技术人员公知的(Carrillo,H.&Lipman,D.,SIAM J Applied Math 48:1073(1988))。
如本文所使用的,术语“Th细胞辅助表位”是指使辅助T细胞活化的所有表位,包括PADRE。PADRE为13个氨基酸的短肽序列,能人和多种动物不同DR分子结合,提呈于细胞表面,进而激活CD4+T辅助细胞,发挥免疫调节作用。PADRE诱导T细胞应答的能力是天然表位的1000倍以上,因此PADRE具备作为免疫佐剂的一些特征。PADRE肽段在体内可以免疫性激活辅助型T细胞(Th1)以协助CTL的激活,并且可以激活辅助型T细胞(Th2)以协助B细胞分泌特异性抗体,进而进一步增强重组蛋白所引起的抗原免疫反应。
如本文所使用的,术语“疾病”或“病状”是指能够用本文提供的融合蛋白、药物组合物或方法治疗的患者或个体的生存状态或健康状态。
术语“疫苗”是纯化的抗原疫苗或免疫原性组合物,亚基疫苗或免疫原性组合物,灭活的整体病毒疫苗或免疫原性组合物,或减毒病毒疫苗或免疫原性组合物。在一些实施方案中,疫苗或免疫原性组合物是纯化的融合蛋白。
如本文所使用的,术语“治疗(treating或treatment)”是指成功治疗或改善损伤、疾病、病理或病状(condition)的任何指标,包含任何客观或主观参数,如,消除;缓解;减轻症状或使得损伤、病理或病状对患者而言更易忍受;减缓退化或衰退的速度;或使退化的最终点较少衰退;改善患者的身体或精神健康。症状的治疗或改善可以基于客观或主观参数;包含身体检查、神经精神病学检查和/或精神病学评估的结果。术语“治疗”及其缀合可以包含预防损伤、病理、病状或疾病。在实施例中,治疗是预防。在实施例中,治疗不包含预防。
如本文所使用的(并且在本领域中被充分理解的),“治疗(treating或treatment)”还广泛地包含用于在受试者的病状中获得有益的或期望的结果(包含临床结果)的任何方法。有益的或期望的临床结果可以包含但不限于:减轻或改善一种或多种症状或病状、减轻疾病程度、稳定(即,不恶化)疾病状态、预防疾病传播或扩散、延迟或减缓疾病进展、改善或缓解疾病状态、减少疾病复发以及缓解(无论是部分的还是全部的,以及无论是可检测的还是不可检测的)。换句话说,如本文所使用的,“治疗”包含对疾病的任何治愈、改善或预防。治疗可以预防疾病发生;抑制疾病扩散;缓解疾病的症状、完全或部分去除疾病的根本原因、缩短疾病的持续时间或这些事物的组合。
如本文所使用的,“治疗(Treating和treatment)”包含预防性治疗。治疗方法包含向受试者施用治疗有效量的活性剂。施用步骤可以由单次施用组成,或者可以包含一系列施用。治疗期的长度取决于多种因素,如病状的严重程度、患者的年龄、活性剂的浓度、在治疗中所使用的组合物的活性或其组合。还应当理解,用于治疗或预防的药剂的有效剂量可以在特定治疗或预防方案的过程中增加或减少。通过本领域中已知的标准诊断测定,剂量的变化可以产生并且变得显而易见。在一些情况下,可能需要慢性施用。例如,以足以治疗患者的量向受试者施用组合物,且持续足够的持续时间。
如本文所使用的,术语“预防”是指减少患者的疾病症状的发生。如上所述,预防可以是完全的(没有可检测的症状)或部分的,使得观察到比不存在治疗时可能发生的症状更少的症状。
如本文所使用的,“患者”或“有需要的受试者”是指遭受或易于遭受可以通过施用如本文所提供的药物组合物进行治疗的疾病或病状的活生物体。非限制性实例包含人、其它哺乳动物、牛科动物、大鼠、小鼠、狗、猴、山羊、绵羊、牛、鹿和其它非哺乳动物。在一些实施例中,患者是人。
术语“联合给药”是指将本公开的融合蛋白或疫苗与已知药物(或其它化合物,或其它疫苗)进行“联合用药”,从而二者都具有治疗或诊断效果。这种联合用药可以包括相对于施用本公开的融合蛋白或疫苗而言对该药物(或其它化合物,或其它疫苗)进行并行(即同时)、在前或相继给药。本领域一般技术人员将能够很容易判断特定药物(或其它化合物,或其它疫苗)以及本公开的联合物的合适的给药时间、顺序和剂量。
如本文所使用的,术语“有效量”是足以实现所陈述目的的量(例如实现它被施用来达成的作用,治疗疾病,降低酶活性,增加酶活性,降低蛋白质功能,减轻疾病或病状的一种或多种症状)。“有效量”的实例是足以促成治疗、预防或减少疾病的一种或多种症状的量,所述量也可以被称为“治疗有效量”。一种或多种症状的“减少”意指降低一种或多种症状的严重程度或频率,或消除一种或多种症状。药物的“预防有效量”是当施用于受试者时,将具有预期的预防效果的药物的量,例如预防或延迟损伤、疾病、病理或病状的发作(或复发)或降低损伤、疾病、病理或病状或其症状发作(或复发)的可能性。完全预防效果不一定通过施用一次剂量发生,并且可以在仅施用一系列剂量之后发生。因此,预防有效量可以以一次或多次施用的形式施用。
如本文所使用的,术语“治疗有效量”是指如上文所描述的足以改善病症的治疗剂的量。例如,对于给定参数,治疗有效量将显示增加或降低至少5%、10%、15%、20%、25%、40%、50%、60%、75%、80%、90%或至少100%。治疗功效也可以表示为“倍数”增加或减少。例如,治疗有效量可以相对于对照具有至少1.2倍、1.5倍、2倍、5倍或更多的效果。
剂量可以根据患者的需要和所采用的融合蛋白或疫苗而变化。在本公开的上下文中,向患者施用的剂量应足以随时间推移而在患者体内产生有益治疗反应。剂量的大小也将通过任何不良副作用的存在、性质和程度确定。针对特定情况来确定适当的剂量是在执业者的技能之内的。通常,治疗开始于比融合蛋白或疫苗的最优剂量小的较小剂量。其后,剂量以小增量增加直到达到在这些情况下的最优效果。可以单独调整给药的量和间隔,以提供所施用融合蛋白或疫苗的对所治疗的特定临床适应症有效的水平。这将提供与个体疾病状态的严重程度相称的治疗方案。
如本文所使用的,术语“施用”意指向受试者口服施用、以栓剂形式施用、局部接触、静脉内、肠胃外、腹膜内、肌肉内、病灶内、鞘内、鼻内或皮下施用,或植入缓慢释放装置(例如,微型渗透泵)。通过任何途径进行施用,包含肠胃外和经粘膜(例如,颊、舌下、腭、牙龈、鼻、阴道、直肠或经皮)。肠胃外施用包含例如静脉内、肌肉内、动脉内、皮内、皮下、腹膜内、心室内和颅内施用。其它递送模式包含但不限于使用脂质体调配物、静脉内输注、经皮贴剂等。在实施例中,施用不包含施用除了所叙述的活性剂之外的任何活性剂。
II.疫苗
在一方面,本公开提供了一种治疗或预防与SARS-CoV-2相关的疾病或病状的疫苗组合产品,所述疫苗组合产品包含:
(i)亲本株疫苗,所述亲本株疫苗包含野生型SARS-CoV-2多肽的融合蛋白,所述野生型SARS-CoV-2融合蛋白包含:(1)干扰素或其功能片段;(2)野生型SARS-CoV-2的S蛋白的RBD或其功能片段;和(3)免疫球蛋白Fc区;和
(ii)突变株疫苗,所述突变株疫苗包含突变型SARS-CoV-2多肽的融合蛋白,所述突变型SARS-CoV-2融合蛋白包含:(1)干扰素或其功能片段;(2)突变型SARS-CoV-2的S蛋白的RBD或其功能片段;和(3)免疫球蛋白Fc区;
其中,所述亲本株疫苗或所述突变株疫苗中的一种作为引发疫苗施用,所述亲本株疫苗或所述突变株疫苗中的一种作为加强疫苗施用,并且所述亲本株疫苗和所述突变株疫苗两者均被施用。
在一些实施方案中,所述干扰素选自I型干扰素、II型干扰素和/或III型干扰素。
在一些实施方案中,所述干扰素可来自人源或鼠源。
在一些实施方案中,所述I型干扰素选自IFN-α、IFN-β、IFN-κ、IFN-δ、IFN-ε、IFN-τ、IFN-ω和IFN-ζ。
在一些实施方案中,所述II型干扰素为干扰素γ。
在一些实施方案中,所述III型干扰素选自IFN-λ1(IL-29)、IFN-λ2(IL-28a)和IFN-λ(IL-28b)。
在一些实施方案中,所述干扰素选自人IFN-α1、IFN-α2、IFN-α4、IFN-α5、IFN-α6、IFN-α7、IFN-α8、IFN-α10、IFN-α13、IFN-α14、IFN-α16、IFN-α17和IFN-α21;
更优选地,所述干扰素为IFN-α2a;优选地,所述IFN-α2a的氨基酸序列包含与SEQID NO 1所示氨基酸序列具有80%或以上同一性的氨基酸序列,优选具有85%、90%、95%、96%、97%、98%、99%以上同一性的氨基酸序列,更优选具有98%或99%以上同一性的氨基酸序列;更优选地,所述IFN-α-2a的氨基酸序列如SEQ ID NO:1所示。
在一些实施方案中,所述野生型SARS-CoV-2的S蛋白的RBD包含与SEQ ID NO 2所示的氨基酸序列具有80%或以上同一性的氨基酸序列,优选具有85%、90%、95%、96%、97%、98%、99%以上同一性的氨基酸序列,更优选具有98%或99%以上同一性的氨基酸序列;更优选地,所述野生型SARS-CoV-2的S蛋白的RBD的氨基酸序列如SEQ ID NO:2所示。
在一些实施方案中,所述突变型SARS-CoV-2的S蛋白的RBD包含与SEQ ID NO 3所示的氨基酸序列具有80%或以上同一性的氨基酸序列,优选具有85%、90%、95%、96%、97%、98%、99%以上同一性的氨基酸序列,更优选具有98%或99%以上同一性的氨基酸序列;更优选地,所述突变型SARS-CoV-2的S蛋白的RBD的氨基酸序列如SEQ ID NO:3所示。
在一些实施方案中,所述免疫球蛋白Fc区选自IgG1、IgG2、IgG3和/或IgG4的恒定区氨基酸序列。
在一些实施方案中,所述免疫球蛋白Fc区为IgG1的Fc区;优选地,所述IgG1 Fc区包含与SEQ ID NO 4所示氨基酸序列具有80%或以上同一性的氨基酸序列,优选具有85%、90%、95%、96%、97%、98%、99%以上同一性的氨基酸序列,更优选具有98%或99%以上同一性的氨基酸序列;更优选地,所述IgG1 Fc区的氨基酸序列如SEQ ID NO 4所示。
在一些实施方案中,所述融合蛋白还包含一个或多个Th细胞辅助表位和/或连接片段。
在一些实施方案中,所述Th细胞辅助表位为PADRE或其衍生物;所述PADRE或其衍生物的氨基酸序列选自SEQ ID NO 5、SEQ ID NO 6、SEQ ID NO 7、SEQ ID NO 8、SEQ ID NO9和SEQ ID NO10。
在一些实施方案中,所述连接片段为柔多肽序列;优选地,所述柔性肽的氨基酸序列选自SEQ ID NO 11和SEQ ID NO 12。
在一些实施方案中,所述亲本株疫苗和/或所述突变株疫苗独立地还包含一种或更多种药学上可接受的载体、赋形剂、稀释剂或佐剂。
在一些实施方案中,所述佐剂选自氢氧化铝、磷酸铝、皂苷例如Quil A、QS-21(Cambridge Biotech Inc.,CambridgeMA)、GPI-0100(Galenica Pharmaceuticals,Inc.,Birmingham,AL)、油包水型乳状液、水包油型乳状液、水包油包水型乳状液。
在一些实施方案中,其中所述亲本株疫苗和/或所述突变株疫苗呈液体、乳液、固体、气雾剂、薄雾或气体的形式。
在一些实施方案中,所述野生型SARS-CoV-2的融合蛋白包含与选自SEQ ID NO 13所示氨基酸序列具有80%或以上同一性的氨基酸序列,优选具有85%、90%、95%、96%、97%、98%、99%以上同一性的氨基酸序列,更优选具有98%或99%以上同一性的氨基酸序列;优选地,所述野生型SARS-CoV-2的融合蛋白的氨基酸序列如SEQ ID NO 13所示。
在一些实施方案中,所述突变型SARS-CoV-2的融合蛋白包含与选自SEQ ID NO 14所示氨基酸序列具有80%或以上同一性的氨基酸序列,优选具有85%、90%、95%、96%、97%、98%、99%以上同一性的氨基酸序列,更优选具有98%或99%以上同一性的氨基酸序列;优选地,所述突变型SARS-CoV-2的融合蛋白的氨基酸序列如SEQ ID NO 14所示。
在一些实施方案中,所述突变株疫苗是引发疫苗,并且所述亲本株疫苗是加强疫苗。
在一些实施方案中,所述亲本株疫苗是引发疫苗,并且所述突变株疫苗是加强疫苗。
在一些实施方案中,所述加强疫苗在所述引发疫苗初始给予后间隔一段时间给予以进行免疫。
在一些实施方案中,所述加强疫苗在所述引发疫苗初始给予后间隔一段时间首次给予以进行第一次加强免疫,并且,所述加强疫苗在引发疫苗初始给予后间隔另一段时间再次给予以进行第二次加强免疫;优选地,所述亲本株疫苗是引发疫苗,并且所述突变株疫苗是加强疫苗,所述突变株疫苗在所述亲本株疫苗初始给予后间隔一段时间首次给予,并且,所述突变株疫苗在亲本株疫苗初始给予后间隔另一段时间再次给予。
在一些实施方案中,所述引发疫苗在所述引发疫苗初始给予后间隔一段时间再次给予以进行第一次加强免疫,并且,所述加强疫苗在引发疫苗初始给予后间隔另一段时间首次给予以进行第二次加强免疫;优选地,所述亲本株疫苗是引发疫苗,并且所述突变株疫苗是加强疫苗,所述亲本株疫苗在所述亲本株疫苗初始给予后间隔一段时间再次给予,并且,所述突变株疫苗在亲本株疫苗初始给予后间隔另一段时间首次给予。
在一些实施方案中,所述加强疫苗在所述引发疫苗初始给予后大约1-10周给予,优选2-8、3-8、1-3、2-5、2-3、3-5、5-8周给予,更优选2-8、2-5,3-5周给予。
在一些实施方案中,所述加强疫苗在所述引发疫苗初始给予后大约1-10周首次给予,优选2-8、3-8、1-3、2-5、2-3、3-5、5-8周首次给予,更优选2-8、2-5,3-5周首次给予;所述加强疫苗在所述引发疫苗初始给予后大约4-72周再次给予,优选6-52、6-45、6-30、6-25、8-52、8-30、8-25、4-12周,更优选4-12、6-25、8-25周再次给予。
在一些实施方案中,所述引发疫苗在所述引发疫苗初始给予后大约1-10周再次给予,优选2-8、3-8、1-3、2-5、2-3、3-5、5-8周再次给予,更优选2-8、2-5,3-5周再次给予;所述加强疫苗在所述引发疫苗初始给予后大约4-72周首次给予,优选6-52、6-45、6-30、6-25、8-52、8-30、8-25、4-12周,更优选4-12、6-25、8-25周首次给予。
在一些实施方案中,所述加强疫苗在所述引发疫苗初始给予后大约2-5周首次给予,并在所述引发疫苗初始给予后大约6-25周再次给予。
在一些实施方案中,所述引发疫苗在所述引发疫苗初始给予后大约2-5周再次给予,所述加强疫苗在所述引发疫苗初始给予后大约6-25周首次给予。
在另一方面,本公开提供了编码所述的疫苗组合产品的核酸。
在一些实施方案中,所述包含野生型SARS-CoV-2多肽融合蛋白的编码核酸包含与SEQ ID NO:15所示核苷酸序列具有80%或以上同一性的核苷酸序列,优选具有85%、90%、95%、96%、97%、98%、99%以上同一性的核苷酸列,更优选具有98%或99%以上同一性的核苷酸序列;所述野生型SARS-CoV-2的融合蛋白的编码核酸为SEQ ID NO 15所示的核酸。
在一些实施方案中,所述包含突变型SARS-CoV-2多肽融合蛋白的编码核酸包含与SEQ ID NO:16所示核苷酸序列具有80%或以上同一性的核苷酸序列,优选具有85%、90%、95%、96%、97%、98%、99%以上同一性的核苷酸列,更优选具有98%或99%以上同一性的核苷酸序列;所述突变型SARS-CoV-2融合蛋白的编码核酸为SEQ ID NO 16所示的核酸。
在一些实施方案中,所述核酸是mRNA。
在另一方面,本公开提供了一种包含所述核酸的表达载体。
在一些实施方案中,所述表达载体是哺乳动物细胞表达载体。
在一些实施方案中,所述表达载体选自质粒、粘粒、病毒载体、RNA载体或线性或圆形DNA或RNA分子。
在一些实施方案中,所述质粒选自pCI、puc57、pcDNA3、pSG5、pJ603和pCMV。
在一些实施方案中,所述病毒载体选自腺病毒、逆转录病毒、细小病毒(例如,腺伴随病毒)、冠状病毒、负链RNA病毒诸如正粘病毒(例如,流感病毒)、弹状病毒(例如,狂犬病和水疱性口炎病毒)、副粘病毒(例如,麻疼和仙台)、正链RNA病毒诸如小RNA病毒和甲病毒,和双链DNA病毒。
在一些实施方案中,所述腺病毒载体选自人、黑猩猩或恒河猴腺病毒;优选地,所述腺病毒选自血清型Ad2、Ad4、Ad5、Ad6、Ad11、Ad12、Ad24、Ad26、Ad34、Ad35、Ad40、Ad48、Ad49、Ad50、Ad52和Pan9腺病毒
优选地,所述逆转录病毒选自禽造白细胞组织增生-肉瘤、哺乳动物C-型、B-型病毒、D-型病毒、HTLV-BLV集合、慢病毒和泡沫病毒;
优选地,所述慢病毒载体选自HIV-1、HIV_2、SIV、FIV、BIV、EIAV、CAEV和绵羊脱髓鞘性脑白质炎慢病毒;
优选地,所述双链DNA病毒包括腺病毒、疱疹病毒(例如,单纯疱疹病毒1和2型、愛泼斯坦-巴尔病毒、巨细胞病毒)和痘病毒(例如,牛痘病毒、鸡痘病毒和金丝雀痘病毒)、诺沃克病毒、披膜病毒、黄病毒、呼肠孤病毒、乳多泡病毒、嗜肝DNA病毒、杆状病毒和肝炎病毒。
核酸分子也可以插入表达载体,诸如腺病毒载体中,并掺入本公开的组合物中。术语“腺病毒载体(adenovirus vector)”和“腺病毒载体(adenoviral vector)”和“腺病毒颗粒”可互换使用,是指经基因工程改造的腺病毒,其设计为将目标多核苷酸(例如,编码ZIKVM和Env抗原的多核苷酸)插入真核细胞中,使得该多核苷酸随后表达。可用作本公开的病毒载体的腺病毒的实例包括具有或衍生自血清型Ad2、Ad 4、Ad5、Ad6、Ad11、Ad12、Ad24、Ad26、Ad34、Ad35、Ad40、Ad48、Ad49、Ad50、Ad52(例如,RhAd52)和Pan9(也称为AdC68)的那些腺病毒;这些载体可以源自例如人、黑猩猩(例如,ChAd1、ChAd3、ChAd7、ChAd8、ChAd21、ChAd22、ChAd23、ChAd24、ChAd25、ChAd26、ChAd27.1、ChAd28.1、ChAd29、ChAd30、ChAd31.1、ChAd32、ChAd33、ChAd34、ChAd35.1、ChAd36、ChAd37.2、ChAd39、ChAd40.1、ChAd41.1、ChAd42.1、ChAd43、ChAd44、ChAd45、ChAd46、ChAd48、ChAd49、ChAd49、ChAd50、ChAd67或SA7P)或恒河猴腺病毒(例如rhAd51、rhAd52或rhAd53)。
在一些实施方案中,所述逆转录病毒选自禽造白细胞组织增生-肉瘤、哺乳动物C-型、B-型病毒、D-型病毒、HTLV-BLV集合、慢病毒和泡沫病毒。
在一些实施方案中,所述慢病毒载体选自HIV-1、HIV_2、SIV、FIV、BIV、EIAV、CAEV和绵羊脱髓鞘性脑白质炎慢病毒。
在一些实施方案中,所述双链DNA病毒包括腺病毒、疱疹病毒(例如,单纯疱疹病毒1和2型、愛泼斯坦-巴尔病毒、巨细胞病毒)和痘病毒(例如,牛痘病毒、鸡痘病毒和金丝雀痘病毒)、诺沃克病毒、披膜病毒、黄病毒、呼肠孤病毒、乳多泡病毒、嗜肝DNA病毒、杆状病毒和肝炎病毒。
在另一方面,本公开提供了一种表达所述疫苗组合产品、包含所述核酸和/或包含所述表达载体的宿主细胞。
在一些实施方案中,所述宿主细胞是原核细胞或真核细胞。
在一些实施方案中,所述原核细胞是细菌细胞;优选地,所述原核细胞是大肠杆菌细胞。
在一些实施方案中,所述真核细胞选自酵母细胞、昆虫细胞和哺乳动物细胞;优选地,所述哺乳动物细胞选自CHO、HEK293、SP2/0、BHK、C127等;更优选地,所述真核细胞为CHO细胞。
在一些实施方案中,所述与SARS-CoV-2相关的疾病或病状为SARS-CoV-2感染或COVID-19。
亲本株疫苗和突变株疫苗可以组合药盒呈现。本文所用的术语“组合药盒”或“成套药盒”指一种或多种药物组合物根据本公开用于施用亲本株疫苗和突变株疫苗。所述组合药盒包含分开的药物组合物中的亲本株疫苗和突变株疫苗,其中亲本株疫苗和突变株疫苗在在分开包装的单独药物组合物中。
在本公开的一个实施方式中,所述成套药盒包括以下组分:
亲本株疫苗,与药学上可接受载体、稀释剂或赋形剂联合;
突变株疫苗,与药学上可接受载体、稀释剂或赋形剂联合;
其中所述组分以适合顺序、分开施用的形式提供。
在一个实施方式中,所述成套药盒,其包括:
含亲本株疫苗与药学上可接受载体、稀释剂或赋形剂的第一容器;和含突变株疫苗与药学上可接受载体、稀释剂或赋形剂的第二容器。
所述试剂盒或组合药盒还能根据有说明,如剂量和施用说明。这种剂量和施用说明可以是提供给医生的类型例如药品标签,或可以是由医生提供的类型,如给患者的说明。
所用药物组合物或疫苗的这些要素可以单独药物组合呈现或以共同配制于一种药物组合物中。因此,本公开还提供多个药物组合物或疫苗的组合,药物组合物或疫苗其中之一含有亲本株疫苗和一种或多种药学上可接受载体、稀释剂或赋形剂的药物组合物以及一种药物组合物含有突变株疫苗和一种或多种药学上可接受载体、稀释剂或赋形剂的药物组合物。
药物组合物或疫苗可以每单位剂量含预定量活性成分的单位剂型呈现。如本领域技术人员已知,每剂量的活性成分的量取决于所治疗病症、施用途径以及患者的年龄、体重和状况。优选的单位剂量组合物含有活性成分的日剂量或亚剂量或其合适部分。此外,这种药物组合物可通过制药领域熟知的任何方法制备。
药物组合物或疫苗可通过任何合适途径施用。合适的途径包括口服、直肠、鼻、局部(包括颊和舌下)、阴道和胃肠外(包括皮下、肌肉、静脉、皮内、鞘内和硬脑膜外)。应理解施用的各试剂可经相同或不同途径施用且亲本株疫苗和突变株疫苗处于分开的药物组合物中。
本公开的药物组合物或疫苗一般适合于肠胃外施用。如本文所使用的,药物组合物或疫苗的“肠胃外施用”包括特征在于受试者组织的物理伤口的任何施用途径和药物组合物或疫苗通过组织中的伤口的施用,从而一般导致直接施用到到肌肉内、或到内脏器官内。肠胃外施用因此包括但不限于,通过注射组合物施用药物组合物,通过外科切口应用组合物,通过组织穿透非外科创伤应用组合物等。特别地,肠胃外施用考虑包括但不限于,皮下、肌内注射或输注。
适合于肠胃外施用的药物组合物或疫苗的制剂一般包含与药学上可接受的载体组合的活性成分,所述载体例如无菌水或无菌等渗盐水。此种制剂可以以适合于推注施用或连续施用形式进行配制、包装或销售。可注射制剂可以以单位剂型,例如在包含防腐剂的安瓿或多剂量容器中进行配制、包装或销售。用于肠胃外施用的制剂包括但不限于,在油或水媒介物中的悬浮液、溶液、乳状液、糊剂等。此种制剂可以进一步包含一种或多种另外的成分,包括但不限于悬浮、稳定或分散剂。在用于肠胃外施用的制剂的一个实施方案中,活性成分以干燥(即粉剂或粒剂)形式提供,用于在重构组合物的肠胃外施用前用合适的媒介物(例如灭菌无热原水)重构。肠胃外制剂还包括水溶液,其可以包含赋形剂例如盐、碳水化合物和缓冲剂(优选至3-9的pH),但对于某些应用,它们可以更适合于配制为无菌非水溶液或干燥形式,以与合适的媒介物例如灭菌、无热原水结合使用。示例性肠胃外施用形式包括在无菌水溶液中的溶液或悬浮液,例如丙二醇或右旋糖水溶液。需要时,此种剂型可以进行适当缓冲。有用的其他肠胃外可施用的制剂包括包含以微晶形式或在脂质体制剂中的活性成分的那些。用于肠胃外施用的制剂可以配制为立即和/或缓和释放的。缓和释放制剂包括延迟、持续、脉冲、控制、靶向和按程序释放。
例如,在一个方面,无菌可注射溶液可以通过将所需量的药物组合物或疫苗与上文列出的成分之一或组合掺入合适溶剂中进行制备,需要时,随后为过滤灭菌。一般地,分散系通过将活性化合物掺入无菌媒介物中进行制备,所述无菌媒介物包含基本分散介质和来自上文列出那些的所需其他成分。在用于制备无菌可注射溶液的无菌粉剂的情况下,优选制备方法是真空干燥和冷冻干燥,这产生来自其先前无菌过滤溶液的活性成分加任何另外所需成分的粉末。溶液的合适流动性可以这样得到维持:例如通过使用包衣例如卵磷脂、在分散系的情况下通过维持所需粒子大小和通过使用表面活性剂。可注射组合物的延长吸收可以通过在组合物中包括延迟吸收的试剂例如单硬脂酸盐和明胶来达到。
本公开的抗体还可以鼻内或通过吸入进行施用,一般以来自干粉吸入器的干粉(单独,作为混合物,或作为混合组分颗粒,例如与合适的药学上可接受的赋形剂混合)形式,作为来自增压容器、泵、喷射器、喷雾器(优选使用电流体动力学的喷雾器以产生精细薄雾)或雾化器的气溶胶喷雾,连同使用或不使用合适的推进剂,或作为滴鼻剂。
增压容器、泵、喷射器、喷雾器或雾化器一般包含本公开抗体的溶液或悬浮液,其包含例如合适的试剂用于分散、溶解或延长活性的释放,一种或多种推进剂作为溶剂。
在以干粉或悬浮制剂使用前,药物产品一般微粒化至适合于通过吸入递送的大小(一般小于5微米)。这可以通过任何合适的粉碎方法来达到,所述方法例如螺旋气流磨、流体床气流磨、超临界流体加工以形成纳米颗粒、高压均质化、或喷雾干燥。
可以配制用于在吸入器或吹入器中使用的胶囊、水泡和药筒,以包含本公开化合物、合适的粉基和性能改良剂的粉末混合物。用于在使用电流体动力学以产生精细薄雾的喷雾器中使用的合适的溶液制剂可以包含合适剂量的本公开抗体/启动,并且启动体积可以例如从1μL到100μL不等。
合适的调味剂例如薄荷和左薄荷脑或甜味剂例如糖精或糖精钠,可以加入预期用于吸入/鼻内施用的本公开的这些制剂中。
用于吸入/鼻内施用的制剂可以配制为立即和/或缓和释放的。缓和释放制剂包括延迟、持续、脉冲、控制、靶向和按程序释放。
在干粉吸入器和气溶胶的情况下,剂量单位借助于递送测定量的阀进行确定。依照本公开的单位一般安排为施用本公开抗体的测定量或“团(puff)”。总日剂量一般将以单次剂量或更通常地作为全天的分份剂量进行施用。
本公开的药物组合物或疫苗也可以配制用于口部途径施用。适合口服施用的药物组合物或疫苗可作为独立单元,如胶囊剂或片剂;粉末剂或颗粒剂;水性或非水性液体中的溶液剂或混悬剂;可食用泡沫或奶油;或水包油液体乳剂或油包水液体乳剂呈现。
例如,对于片剂或胶囊剂形式的口服施用,活性药物组分能与口服、无毒的药学上可接受惰性载体如乙醇、甘油、水等组合。粉末如下制备:粉碎化合物至合适细粒度,并与类似粉碎的药物载体如可食用碳水化合物(例如淀粉或甘露醇)混合。增味剂、防腐剂、分散剂和着色剂也能存在。
胶囊如下制备:如上所述制备粉末混合物,填充形成的胶囊套。助流剂和润滑剂如硅胶、滑石、硬脂酸镁、硬脂酸钙或固体聚乙二醇能在填充操作前加入粉末混合物。还可加入崩解剂或增溶剂如琼脂-琼脂、碳酸钙或碳酸钠以改善吞咽胶囊时的药物利用度。
此外,需要或必要时,合适的粘合剂、润滑剂、崩解剂和着色剂也能造粒,粉末混合物可经过压片机,结果是未完全形成的小块会碎成颗粒。颗粒能经润滑纳入混合物。合适的粘合剂包括淀粉、明胶、天然糖如葡萄糖或β-乳糖、玉米甜味剂、天然和合成树胶如阿拉伯胶、黄芪胶或藻酸钠、羧甲基纤维素、聚乙二醇、蜡等。用于这些剂型的润滑剂包括油酸钠、硬脂酸钠、硬脂酸镁、苯甲酸钠、乙酸钠、氯化纳等。崩解剂包括但不限于淀粉、甲基纤维素、琼脂、皂土、黄原胶等。配制片剂,例如通过制备粉末混合物,造粒或冲击,加入润滑剂和崩解剂并压成片剂。粉末混合物如下制备:如上所述将适当粉碎的化合物与稀释剂或基质混合,可选联同粘合剂如羧甲基纤维素、藻酸盐、明胶或聚乙烯吡咯烷酮,溶液阻滞剂如石蜡,再吸收促进剂如季盐和/或吸收剂如皂土、高岭土或磷酸氢钙。粉末混合物能如下造粒:用粘合剂如糖浆、淀粉糊、阿拉伯胶粘液(acadiamucilage)或者纤维素或聚合材料溶液湿润,并迫使过筛。防止粘住压片模具的替代方式是加入硬脂酸、硬脂酸盐、滑石或矿物油。然后,润滑的混合物压成片剂。本公开化合物还能与自由流动的惰性载体组合并直接压成片剂,而不需经历造粒或冲击步骤。可提供澄清或不透明的保护包衣,所述包衣由虫胶密封涂层、糖或聚合材料的涂层和蜡的抛光涂层组成。能向这些包衣加入染料以区分不同单位剂量。
口服液体如溶液、糖浆和酏剂能以单位剂型制备,从而给定量包含预定量的化合物。通过将化合物溶于适当调味的水溶液可制备糖浆,使用无毒醇载剂制备酏剂。通过将化合物分散于无毒载剂可配制混悬剂。还能加入增溶剂和乳化剂如乙氧基化异硬脂醇及聚氧乙烯山梨醇醚、防腐剂、香味添加剂如薄荷油或天然甜味剂或糖精或其它人造甜味剂等。
适当时,口服施用的组合物能装入微胶囊。所述组合物还能制备成延长或维持释放,例如通过将微粒材料包被或包埋于聚合物、蜡等。
根据本公开使用的试剂还可以脂质体递送系统形式施用,如小单层囊泡、大单层囊泡和多层囊泡。脂质体能形成自多种磷脂,如胆固醇、硬脂胺或磷脂酰胆碱。
适合经皮施用的药物组合物可作为独立贴片呈现,贴片旨在维持与受体表皮的长时间密切接触。例如,活性成分可通过离子导入法从贴片递送。
适合局部施用的药物组合物可配制成软膏剂、乳膏剂、混悬剂、洗剂、粉末剂、溶液剂、糊剂、凝胶剂、喷雾剂、气雾剂或油剂。
适合口腔局部施用的药物组合物包括锭剂、糖果锭剂和漱口剂。
适合直肠施用的药物组合物可以为栓剂或灌肠剂。
在另一方面,本公开提供了一种试剂盒,其包含所述疫苗组合产品、所述核酸、所述表达载体和/或所述宿主细胞。
在另一方面,本公开提供了所述试剂盒在制备用于在有相应需要的受试者中诱导针对SARS-CoV-2的免疫应答的药物组合物中的用途。
III.疫苗的联合用药
在另一方面,本公开提供了一种亲本株疫苗和突变株疫苗在制备治疗或预防与SARS-CoV-2相关的疾病或病状的疫苗组合产品中的用途。
在另一方面,本公开提供了本公开提供了一种在有相应需要的受试者中诱导针对新型冠状病毒SARS-CoV-2的免疫应答的方法,所述方法包括:
(i)向受试者施用亲本株疫苗;和
(ii)向受试者施用突变株疫苗。
在一些实施方案中,所述突变株疫苗是引发疫苗,并且所述亲本株疫苗是加强疫苗。
在一些实施方案中,所述亲本株疫苗是引发疫苗,并且所述突变株疫苗是加强疫苗。
在一些实施方案中,所述加强疫苗在所述引发疫苗初始给予后大约1-10周首次给予。
在一些实施方案中,所述加强疫苗在所述引发疫苗初始给予后大约1-10周给予,优选2-8、3-8、1-3、2-5、2-3、3-5、5-8周给予,更优选2-8、2-5,3-5周给予。
在一些实施方案中,所述加强疫苗在所述引发疫苗初始给予后大约1-10周首次给予,优选2-8、3-8、1-3、2-5、2-3、3-5、5-8周首次给予,更优选2-8、2-5,3-5周首次给予;所述加强疫苗在所述引发疫苗初始给予后大约4-72周再次给予,优选6-52、6-45、6-30、6-25、8-52、8-30、8-25、4-12周,更优选4-12、6-25、8-25周再次给予。
在一些实施方案中,所述引发疫苗在所述引发疫苗初始给予后大约1-10周再次给予,优选2-8、3-8、1-3、2-5、2-3、3-5、5-8周再次给予,更优选2-8、2-5,3-5周再次给予;所述加强疫苗在所述引发疫苗初始给予后大约4-72周首次给予,优选6-52、6-45、6-30、6-25、8-52、8-30、8-25、4-12周,更优选4-12、6-25、8-25周首次给予。
在一些实施方案中,所述加强疫苗在所述引发疫苗初始给予后大约2-5周首次给予,并在所述引发疫苗初始给予后大约6-25周再次给予。
在一些实施方案中,所述引发疫苗在所述引发疫苗初始给予后大约2-5周再次给予,所述加强疫苗在所述引发疫苗初始给予后大约6-25周首次给予
用于给药的剂型包括,例如,口服制剂(例如:片剂、胶囊、颗粒剂、粉剂、口服溶液、糖浆剂、口服胶冻剂等)、口腔黏膜制剂(例如:口腔黏膜应用的片剂、口腔黏膜应用的喷雾剂、口腔黏膜应用的半固体制剂、漱口剂等)、用于注射的制剂(例如:注射剂等)、鼻喷雾剂或滴鼻剂、用于吸入的制剂(例如:雾化吸入剂等)、用于直肠的制剂(例如:栓剂、用于直肠应用的半固体制剂、用于直肠应用的灌肠剂等)、用于皮肤应用的制剂(例如:用于皮肤应用的固体制剂、用于皮肤应用的液体和溶液、喷雾剂、软膏剂、霜剂、凝胶剂、贴剂等)及类似形式。
在一些实施方案中,所述疫苗通过皮内注射、皮下注射、肌肉注射、静脉注射、滴鼻或雾化吸入的方式进行施用。
在一些实施方案中,所述疫苗通过注射进行施用。
本公开提供了一种提高新冠疫苗应对新冠病毒及多种突变株协同免疫效果的免疫程序。综合评估了亲本株与南非株疫苗组成的,包括不同注射部位施打组合、二价混合疫苗组合、不同注射程序组合、等不同免疫程序在小鼠体内产生保护力的差异。本公开的免疫程序可使体内获得更高滴度的中和抗体与更广谱的保护力,可显著提升对新冠病毒及多种突变株病毒的防御能力,达到协同免疫的效果。
为了达到清楚和简洁描述的目的,本文中作为相同的或分开的一些实施方案的一部分来描述特征,然而,将要理解的是,本公开的范围可包括具有所描述的所有或一些特征的联合的一些实施方案。
实施例
实施例1:疫苗的制备
本实施例中的亲本株疫苗(V-01)和突变株疫苗(南非株,V-01-351)均是包含IFN、新冠S蛋白的RBD结构域与IgG Fc的融合蛋白。其中,亲本株疫苗的氨基酸序列如SEQ ID NO13所示,其编码核酸序列如SEQ ID NO 15所示;南非株疫苗的氨基酸序列如SEQ ID NO 14所示,其编码核酸序列如SEQ ID NO 16所示。本实施例涉及的所有基因都是通过全基因合成,然后通过Hind III和Pac I双酶切连接到哺乳细胞表达载体pCGS3(购自:Sigma-Aldrich),分别构建表达亲本株疫苗和突变株疫苗的表达载体,并采用ExpiCHO表达系统对蛋白进行表达,细胞培养液经澄清后的样品直接上Protein A亲和层析柱进行捕获,分别获得纯化的亲本株疫苗和突变株疫苗。
实施例2:小鼠体内效力评估-滴度
疫苗免疫动物后产生特异性的抗体,但该抗体是否能够保护机体不被病毒攻击,还需要进行免疫后血清对于病毒攻击的保护力进行评估。由于新冠病毒的危险性,用真病毒进行攻毒评估非常困难。因此,本实施例采用实施例1制备的亲本株疫苗(V-01,图中简称V01)、突变株疫苗(V-01-351,图中简称351)免疫C57BL/6小鼠,利用重组的新冠病毒S蛋白、以VSV G/HIV为骨架构建包装、并且携带萤光素酶报告基因的假病毒检测免疫后小鼠血清中抗体的中和效价,对亲本株疫苗(V-01)、突变株疫苗(V-01-351)的不同免疫程序的体内效力进行评估。
研究方法:将实施例1制备的亲本株疫苗(V-01)、突变株疫苗(V-01-351)按照不同的免疫程序(表1),分9组免疫6~8周龄C57BL/6小鼠,疫苗浓度20μg/ml,每只小鼠每次大腿肌肉注射0.1mL,10只/组,每只小鼠共免疫2~3次(第0天、第14天、第28天各一次)。初免28天(即2免14天)、初免42天(即3免14天)后眼眶采血,血液室温静置待凝固后,4000rpm,2~8℃,离心10min,取上清。
各组小鼠疫苗接种的免疫程序如下:
表1实验动物分组与疫苗接种的免疫程序
注:(1)“+”表示混合;
(2)第8组和第9组为左腿注射亲本株疫苗(V-01),右腿注射突变株疫苗(V-01-351)。
待测血清样本提前采用56℃水浴灭活30min。取抗新冠病毒S蛋白的RBD小鼠中和抗体(购自novoprotein,货号DA035),先用检测培养液(10%FBS DMEM)稀释至25μg/mL,作为阳性质控品(PC)。取待测血清样本,在96孔全白细胞板中用检测培养液稀释至首孔浓度为5%(即1:20),然后与阳性质控品一起按照1:3进行倍比稀释,共8个稀释梯度,各稀释梯度的血清样本为100μL/孔。提前在4℃融化假病毒,用检测培养液将假病毒(包括野生型假病毒(购自北京天坛生物,货号80033)、南非突变假病毒(购自北京天坛生物,货号80044)、美国突变假病毒(购自南京诺唯赞生物,货号DD1448)、印度一代突变假病毒(购自南京诺唯赞生物,货号DD1452)、印度二代突变假病毒(购自北京天坛生物,货号80048))稀释至20000TCID50/mL,在血清稀释板中加入50μL/孔假病毒稀释液,假病毒量即为1000TCID50/孔,血清初始稀释度即为1:30。同时设置假病毒对照(VC,不含血清)以及细胞对照(CC,不含血清和假病毒),然后将全白细胞板置于37℃、5%CO2培养箱孵育1~2h。收集HEK293T-ACE2细胞(购自吉满生物,货号GM-C09233),用检测培养液重悬计数,并调整细胞浓度至2.5×105个/mL,按照100μL/孔加入细胞,即每孔细胞为2.5×104个。将全白细胞板置于37℃,5%CO2培养箱培养20~28h。检测前先吸弃150μL/孔上清,然后按100μL/孔加入萤光素酶检测试剂,并用多道移液器将反应孔中的液体反复吹吸6~8次,室温避光反应5min。酶标仪读取化学发光单位RLU值,按照如下公式进行抑制率计算:抑制率(%)=[1-(样品组RLU值-细胞对照CC均值)/(假病毒对照VC均值-细胞对照CC均值)]×100%。
将抑制率数据结果导入软件,横坐标为倍比稀释倍数的对数值(Log Titer),纵坐标为抑制率百分比(%Inhibition),进行四参数拟合分析,软件自动计算pNT50值,取整即为假病毒中和效价。
结果与结论:
(1)小鼠体内效力评估-二免与三免比较
如图1所示,对于野生株假病毒,三免后中和效价相比于对应二免提高2.4~7.1倍,各种免疫联合三免后均能达到或超过亲本株疫苗(V-01)二免后的效价水平。
如图2所示,对于南非株(501Y.V2)假病毒,三免后中和效价相比于对应二免提高3.2~9.6倍,且除亲本株疫苗(V-01)三免以外,其他各种免疫联合三免后均能达到或超过突变株疫苗(V-01-351)二免后的效价水平。
如图3所示,对于其他突变假病毒(美国株CAL.20C假病毒、印度株B.1.617.1假病毒和印度株B.1.167.2假病毒),三免后中和效价相比于对应二免有不同比例的提高,且三免后对于美国株假病毒(CAL.20C)和印度株假病毒(B.1.617.1)有较好的中和能力。对于印度株假病毒(B.1.167.2),虽然中和滴度较差,但是三免后中和能力有2~3倍的提升。
(2)小鼠体内效力评估-免疫程序比较
对于野生株假病毒,三免后中和效价由高至低的免疫程序依次为V01+V01+V01>每腿(V01+351)三免>V01+V01+351>V01+351+351>351+351+351。二免后中和效价V01+V01>每腿(V01+351)二免>V01+351>351+351。中和效价均与亲本株疫苗(V-01)的免疫次数呈正相关,各种免疫联合在三免后均能达到或超过亲本株疫苗(V-01)二免后的中和效价水平。
对于南非株假病毒,三免后效价由高至低依次为351+351+351>每腿(V01+351)三免>V01+V01+351>V01+351+351>V01+V01+V01。二免后效价351+351>每腿(V01+351)二免>V01+351>V01+V01。与突变株疫苗(V-01-351)的免疫次数呈一定相关性。各种免疫联合三免后均能对南非株假病毒产生保护效果。
综合考虑野生株和突变株假病毒的情况,亲本株疫苗(V-01)和突变株疫苗(V-01-351)混打的方式(如每腿(V01+351)、V01+V01+351、V01+351+351)均能够兼顾两者,其中每腿一针的免疫程序在效价水平更优,但是其注射次数最多,实操有一定难度。对比V01+V01+351、V01+351+351这两种免疫程序,前者能够在二免后对野生株产生更好的保护效果,三免后对野生株和南非株的保护力更好。因此,两剂亲本株疫苗(V-01)配合一剂突变株疫苗加强针能够产生更为有效的保护效果。
实施例3:联合使用免疫程序比较
实施例2验证了亲本株疫苗(V-01)和突变株疫苗(V-01-351)混打的方式能够产生更好的免疫效果,且每腿一针(V01+351)的方式效价水平更优,本实施例同样利用实施例2中所述假病毒检测免疫后C57BL/6小鼠血清中抗体的中和效价,来比较亲本株疫苗(V-01)和突变株疫苗(V-01-351)不同混打给药方式的免疫程序对免疫效果的影响,具体给药方式如下:
(1)联合注射给药的免疫程序:
左腿注射亲本株疫苗(V-01)、右腿同时注射突变株疫苗(V-01-351),分三组实验,注射不同的剂量,分别为1μg(V-01,左腿)+1μg(V-01-351,右腿)、2μg(V-01,左腿)+2μg(V-01-351,右腿)、2μg(V-01,左腿)+4μg(V-01-351,右腿).
(2)二价苗注射给药的免疫程序:
先预混不同比例的亲本株疫苗(V-01)和突变株疫苗(V-01-351),以混合物的形式注射给药,分三组实验,注射不同的剂量,分别为:1μg(V-01)+1μg(V-01-351)、1μg(V-01)+3μg(V-01-351)、1μg(V-01)+6μg(V-01-351)。
结果与结论:
如图4所示,对于野生株假病毒,混打亲本株疫苗(V-01)和突变株疫苗(V-01-351)二免后,由于联合注射给药和二价苗给药两种免疫方式中亲本株疫苗(V-01)注射剂量相当,效价基本一致,且与亲本株疫苗(V-01)二免后效价相当。
如图5所示,对于南非株假病毒,混打亲本株疫苗(V-01)和突变株疫苗(V-01-351)二免后,联合注射给药和二价苗给药两种免疫方式亦没有呈现明显的剂量依赖趋势,且远低于突变株疫苗(V-01-351)二免后效价。分析原因,可能是突变株疫苗(V-01-351)与亲本株疫苗(V-01)同时注射,两者存在一定的竞争关系,导致突变株疫苗(V-01-351)免疫效果降低。
综合考虑,同时注射亲本株疫苗(V-01)和突变株疫苗(V-01-351),会导致其对南非株假病毒的效价降低,说明同样的疫苗的不同免疫程序也会影响疫苗对人体的免疫保护。
SEQUENCE LISTING
<110> 珠海市丽珠单抗生物技术有限公司
<120> 新型冠状病毒SARS-CoV-2的协同免疫及其用途
<130> MTI21245
<160> 16
<170> PatentIn version 3.5
<210> 1
<211> 165
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 1
Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr Leu Met
1 5 10 15
Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu Lys Asp
20 25 30
Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe Gln
35 40 45
Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe
50 55 60
Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Thr Leu
65 70 75 80
Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu
85 90 95
Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu Met Lys
100 105 110
Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Arg Arg Ile Thr Leu
115 120 125
Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg
130 135 140
Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu Ser
145 150 155 160
Leu Arg Ser Lys Glu
165
<210> 2
<211> 223
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 2
Arg Val Gln Pro Thr Glu Ser Ile Val Arg Phe Pro Asn Ile Thr Asn
1 5 10 15
Leu Cys Pro Phe Gly Glu Val Phe Asn Ala Thr Arg Phe Ala Ser Val
20 25 30
Tyr Ala Trp Asn Arg Lys Arg Ile Ser Asn Cys Val Ala Asp Tyr Ser
35 40 45
Val Leu Tyr Asn Ser Ala Ser Phe Ser Thr Phe Lys Cys Tyr Gly Val
50 55 60
Ser Pro Thr Lys Leu Asn Asp Leu Cys Phe Thr Asn Val Tyr Ala Asp
65 70 75 80
Ser Phe Val Ile Arg Gly Asp Glu Val Arg Gln Ile Ala Pro Gly Gln
85 90 95
Thr Gly Lys Ile Ala Asp Tyr Asn Tyr Lys Leu Pro Asp Asp Phe Thr
100 105 110
Gly Cys Val Ile Ala Trp Asn Ser Asn Asn Leu Asp Ser Lys Val Gly
115 120 125
Gly Asn Tyr Asn Tyr Leu Tyr Arg Leu Phe Arg Lys Ser Asn Leu Lys
130 135 140
Pro Phe Glu Arg Asp Ile Ser Thr Glu Ile Tyr Gln Ala Gly Ser Thr
145 150 155 160
Pro Cys Asn Gly Val Glu Gly Phe Asn Cys Tyr Phe Pro Leu Gln Ser
165 170 175
Tyr Gly Phe Gln Pro Thr Asn Gly Val Gly Tyr Gln Pro Tyr Arg Val
180 185 190
Val Val Leu Ser Phe Glu Leu Leu His Ala Pro Ala Thr Val Cys Gly
195 200 205
Pro Lys Lys Ser Thr Asn Leu Val Lys Asn Lys Cys Val Asn Phe
210 215 220
<210> 3
<211> 223
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 3
Arg Val Gln Pro Thr Glu Ser Ile Val Arg Phe Pro Asn Ile Thr Asn
1 5 10 15
Leu Cys Pro Phe Gly Glu Val Phe Asn Ala Thr Arg Phe Ala Ser Val
20 25 30
Tyr Ala Trp Asn Arg Lys Arg Ile Ser Asn Cys Val Ala Asp Tyr Ser
35 40 45
Val Leu Tyr Asn Ser Ala Ser Phe Ser Thr Phe Lys Cys Tyr Gly Val
50 55 60
Ser Pro Thr Lys Leu Asn Asp Leu Cys Phe Thr Asn Val Tyr Ala Asp
65 70 75 80
Ser Phe Val Ile Arg Gly Asp Glu Val Arg Gln Ile Ala Pro Gly Gln
85 90 95
Thr Gly Asn Ile Ala Asp Tyr Asn Tyr Lys Leu Pro Asp Asp Phe Thr
100 105 110
Gly Cys Val Ile Ala Trp Asn Ser Asn Asn Leu Asp Ser Lys Val Gly
115 120 125
Gly Asn Tyr Asn Tyr Leu Tyr Arg Leu Phe Arg Lys Ser Asn Leu Lys
130 135 140
Pro Phe Glu Arg Asp Ile Ser Thr Glu Ile Tyr Gln Ala Gly Ser Thr
145 150 155 160
Pro Cys Asn Gly Val Lys Gly Phe Asn Cys Tyr Phe Pro Leu Gln Ser
165 170 175
Tyr Gly Phe Gln Pro Thr Tyr Gly Val Gly Tyr Gln Pro Tyr Arg Val
180 185 190
Val Val Leu Ser Phe Glu Leu Leu His Ala Pro Ala Thr Val Cys Gly
195 200 205
Pro Lys Lys Ser Thr Asn Leu Val Lys Asn Lys Cys Val Asn Phe
210 215 220
<210> 4
<211> 232
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 4
Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
1 5 10 15
Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro
20 25 30
Lys Asp Gln Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
35 40 45
Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
50 55 60
Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
65 70 75 80
Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
85 90 95
Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
100 105 110
Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
115 120 125
Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr
130 135 140
Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
145 150 155 160
Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
165 170 175
Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
180 185 190
Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
195 200 205
Ser Cys Ser Val Leu His Glu Ala Leu His Asn His Tyr Thr Gln Lys
210 215 220
Ser Leu Ser Leu Ser Pro Gly Lys
225 230
<210> 5
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 5
Ala Lys Phe Val Ala Ala Trp Thr Leu Lys Ala Ala Ala
1 5 10
<210> 6
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<220>
<221> MOD_RES
<222> (3)..(3)
<223> Xaa 可以是任何天然存在的氨基酸
<400> 6
Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala
1 5 10
<210> 7
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 7
Ala Lys Tyr Val Ala Ala Trp Thr Leu Lys Ala Ala Ala
1 5 10
<210> 8
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 8
Ala Lys Phe Val Ala Ala Tyr Thr Leu Lys Ala Ala Ala
1 5 10
<210> 9
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<220>
<221> MOD_RES
<222> (3)..(3)
<223> Xaa 可以是任何天然存在的氨基酸
<400> 9
Ala Lys Xaa Val Ala Ala Tyr Thr Leu Lys Ala Ala Ala
1 5 10
<210> 10
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 10
Ala Lys Tyr Val Ala Ala Tyr Thr Leu Lys Ala Ala Ala
1 5 10
<210> 11
<211> 15
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 11
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1 5 10 15
<210> 12
<211> 6
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 12
Gly Ser Gly Ser Gly Ser
1 5
<210> 13
<211> 654
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 13
Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr Leu Met
1 5 10 15
Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu Lys Asp
20 25 30
Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe Gln
35 40 45
Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe
50 55 60
Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Thr Leu
65 70 75 80
Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu
85 90 95
Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu Met Lys
100 105 110
Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Arg Arg Ile Thr Leu
115 120 125
Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg
130 135 140
Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu Ser
145 150 155 160
Leu Arg Ser Lys Glu Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
165 170 175
Gly Gly Gly Ser Ala Lys Phe Val Ala Ala Trp Thr Leu Lys Ala Ala
180 185 190
Ala Gly Ser Gly Ser Gly Ser Arg Val Gln Pro Thr Glu Ser Ile Val
195 200 205
Arg Phe Pro Asn Ile Thr Asn Leu Cys Pro Phe Gly Glu Val Phe Asn
210 215 220
Ala Thr Arg Phe Ala Ser Val Tyr Ala Trp Asn Arg Lys Arg Ile Ser
225 230 235 240
Asn Cys Val Ala Asp Tyr Ser Val Leu Tyr Asn Ser Ala Ser Phe Ser
245 250 255
Thr Phe Lys Cys Tyr Gly Val Ser Pro Thr Lys Leu Asn Asp Leu Cys
260 265 270
Phe Thr Asn Val Tyr Ala Asp Ser Phe Val Ile Arg Gly Asp Glu Val
275 280 285
Arg Gln Ile Ala Pro Gly Gln Thr Gly Lys Ile Ala Asp Tyr Asn Tyr
290 295 300
Lys Leu Pro Asp Asp Phe Thr Gly Cys Val Ile Ala Trp Asn Ser Asn
305 310 315 320
Asn Leu Asp Ser Lys Val Gly Gly Asn Tyr Asn Tyr Leu Tyr Arg Leu
325 330 335
Phe Arg Lys Ser Asn Leu Lys Pro Phe Glu Arg Asp Ile Ser Thr Glu
340 345 350
Ile Tyr Gln Ala Gly Ser Thr Pro Cys Asn Gly Val Glu Gly Phe Asn
355 360 365
Cys Tyr Phe Pro Leu Gln Ser Tyr Gly Phe Gln Pro Thr Asn Gly Val
370 375 380
Gly Tyr Gln Pro Tyr Arg Val Val Val Leu Ser Phe Glu Leu Leu His
385 390 395 400
Ala Pro Ala Thr Val Cys Gly Pro Lys Lys Ser Thr Asn Leu Val Lys
405 410 415
Asn Lys Cys Val Asn Phe Glu Pro Lys Ser Cys Asp Lys Thr His Thr
420 425 430
Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
435 440 445
Leu Phe Pro Pro Lys Pro Lys Asp Gln Leu Met Ile Ser Arg Thr Pro
450 455 460
Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
465 470 475 480
Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
485 490 495
Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
500 505 510
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
515 520 525
Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
530 535 540
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
545 550 555 560
Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val
565 570 575
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
580 585 590
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
595 600 605
Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
610 615 620
Gln Gln Gly Asn Val Phe Ser Cys Ser Val Leu His Glu Ala Leu His
625 630 635 640
Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
645 650
<210> 14
<211> 654
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 14
Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr Leu Met
1 5 10 15
Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu Lys Asp
20 25 30
Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe Gln
35 40 45
Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe
50 55 60
Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Thr Leu
65 70 75 80
Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu
85 90 95
Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu Met Lys
100 105 110
Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Arg Arg Ile Thr Leu
115 120 125
Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg
130 135 140
Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu Ser
145 150 155 160
Leu Arg Ser Lys Glu Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
165 170 175
Gly Gly Gly Ser Ala Lys Phe Val Ala Ala Trp Thr Leu Lys Ala Ala
180 185 190
Ala Gly Ser Gly Ser Gly Ser Arg Val Gln Pro Thr Glu Ser Ile Val
195 200 205
Arg Phe Pro Asn Ile Thr Asn Leu Cys Pro Phe Gly Glu Val Phe Asn
210 215 220
Ala Thr Arg Phe Ala Ser Val Tyr Ala Trp Asn Arg Lys Arg Ile Ser
225 230 235 240
Asn Cys Val Ala Asp Tyr Ser Val Leu Tyr Asn Ser Ala Ser Phe Ser
245 250 255
Thr Phe Lys Cys Tyr Gly Val Ser Pro Thr Lys Leu Asn Asp Leu Cys
260 265 270
Phe Thr Asn Val Tyr Ala Asp Ser Phe Val Ile Arg Gly Asp Glu Val
275 280 285
Arg Gln Ile Ala Pro Gly Gln Thr Gly Asn Ile Ala Asp Tyr Asn Tyr
290 295 300
Lys Leu Pro Asp Asp Phe Thr Gly Cys Val Ile Ala Trp Asn Ser Asn
305 310 315 320
Asn Leu Asp Ser Lys Val Gly Gly Asn Tyr Asn Tyr Leu Tyr Arg Leu
325 330 335
Phe Arg Lys Ser Asn Leu Lys Pro Phe Glu Arg Asp Ile Ser Thr Glu
340 345 350
Ile Tyr Gln Ala Gly Ser Thr Pro Cys Asn Gly Val Lys Gly Phe Asn
355 360 365
Cys Tyr Phe Pro Leu Gln Ser Tyr Gly Phe Gln Pro Thr Tyr Gly Val
370 375 380
Gly Tyr Gln Pro Tyr Arg Val Val Val Leu Ser Phe Glu Leu Leu His
385 390 395 400
Ala Pro Ala Thr Val Cys Gly Pro Lys Lys Ser Thr Asn Leu Val Lys
405 410 415
Asn Lys Cys Val Asn Phe Glu Pro Lys Ser Cys Asp Lys Thr His Thr
420 425 430
Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
435 440 445
Leu Phe Pro Pro Lys Pro Lys Asp Gln Leu Met Ile Ser Arg Thr Pro
450 455 460
Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
465 470 475 480
Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
485 490 495
Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
500 505 510
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
515 520 525
Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
530 535 540
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
545 550 555 560
Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val
565 570 575
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
580 585 590
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
595 600 605
Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
610 615 620
Gln Gln Gly Asn Val Phe Ser Cys Ser Val Leu His Glu Ala Leu His
625 630 635 640
Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
645 650
<210> 15
<211> 1962
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 15
tgtgacctgc ctcagaccca tagcctgggc tctaggcgga cactgatgct gctggcccag 60
atgagacgca tctccctgtt tagctgcctg aaggacagac acgatttcgg ctttccacag 120
gaggagttcg gcaatcagtt tcagaaggct gagaccatcc ccgtgctgca tgagatgatc 180
cagcagatct tcaacctgtt ttctacaaag gattccagcg ccgcttggga cgagaccctg 240
ctggataagt tctatacaga gctgtaccag cagctgaatg acctggaggc ctgcgtgatc 300
cagggagtgg gagtgaccga gacaccactg atgaaggagg attctatcct ggctgtgagg 360
aagtatttca ggcggatcac cctgtatctg aaggagaaga agtactcccc ttgtgcctgg 420
gaggtggtga gagctgagat catgcgctct ttttccctga gcacaaacct gcaggagtct 480
ctgcggtcca aggagggagg aggaggatcc ggcggaggag gcagcggagg aggaggatct 540
gccaagtttg tggctgcttg gaccctgaag gctgctgctg gatctggatc cggaagcaga 600
gtgcagccaa ccgagagcat cgtgcgcttc cctaacatca caaatctgtg cccattcggc 660
gaggtgttta atgctacccg ctttgcctcc gtgtacgctt ggaatagaaa gcgcatcagc 720
aactgcgtgg ccgactattc tgtgctgtac aactctgctt ccttcagcac ctttaagtgc 780
tatggcgtga gccccaccaa gctgaatgac ctgtgcttca caaacgtgta cgccgactct 840
tttgtgatca ggggcgatga ggtgcggcag atcgctcctg gacagaccgg caagatcgct 900
gactacaatt ataagctgcc agacgatttc acaggctgcg tgatcgcttg gaactccaac 960
aatctggata gcaaagtggg cggcaactac aattatctgt acaggctgtt ccggaagtcc 1020
aatctgaagc cttttgagag agacatctct accgagatct accaggctgg ctccacacca 1080
tgcaatggcg tggagggctt caactgttat tttcccctgc agtcctacgg cttccagcct 1140
accaacggcg tgggctatca gccataccgc gtggtggtgc tgagctttga gctgctgcac 1200
gctccagcta ccgtgtgcgg acccaagaag tctacaaacc tggtgaagaa taagtgcgtg 1260
aacttcgagc ctaagtcctg tgacaagacc catacatgcc caccttgtcc agctccagag 1320
ctgctgggag gaccaagcgt gttcctgttt ccacccaagc ctaaggatca gctgatgatc 1380
tctaggaccc ccgaggtgac atgcgtggtg gtggacgtgt cccacgagga tcctgaggtg 1440
aagtttaatt ggtacgtgga cggcgtggag gtgcataacg ctaagaccaa gccaagggag 1500
gagcagtata actctaccta ccgggtggtg tccgtgctga cagtgctgca ccaggattgg 1560
ctgaatggca aggagtacaa gtgcaaggtg agcaacaagg ctctgcctgc cccaatcgag 1620
aagaccatct ctaaggccaa gggccagccc agagagcctc aggtgtatac actgcctcca 1680
tcccgcgacg agctgaccaa gaatcaggtg agcctgacat gtctggtgaa gggcttctac 1740
ccaagcgata tcgctgtgga gtgggagtct aacggccagc ccgagaacaa ttataagacc 1800
acaccccctg tgctggacag cgatggctct ttctttctgt actccaagct gaccgtggat 1860
aagagccggt ggcagcaggg caacgtgttc tcctgctccg tgctgcatga ggccctgcac 1920
aaccattaca cacagaagag cctgtctctg tcccccggca ag 1962
<210> 16
<211> 1962
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 16
tgcgacctgc ctcagaccca ctccctgggc tctaggagga ccctcatgct gctggctcag 60
atgagacgga tctctctgtt ctcttgtttg aaggaccggc acgacttcgg ctttcctcag 120
gaagagttcg gcaatcagtt ccagaaggcc gaaaccatcc cagtgctgca cgagatgatc 180
cagcagatct tcaacctgtt ttccaccaag gattcctccg cagcttggga cgagacactg 240
ctggacaagt tctacaccga gctgtaccag cagctgaacg atctggaagc ctgcgtgatc 300
cagggcgtgg gagtgaccga gacacctctg atgaaagagg actctatcct ggccgtgcgg 360
aagtactttc ggagaatcac cctgtacctg aaagaaaaga agtatagccc ctgtgcctgg 420
gaagtggtga gagccgagat catgcggtcc ttcagcctgt ccaccaacct gcaagagagc 480
ctgagatcca aagagggcgg aggcggctct ggcggtggcg gctccggcgg cggagggtcc 540
gccaagttcg tggctgcctg gaccctgaag gccgctgctg gctctggatc tggctcccgc 600
gtgcagccta ccgaaagcat cgtgagattc cctaacatca ccaacctgtg cccctttggc 660
gaggtgttca atgccaccag attcgcctct gtgtacgctt ggaaccggaa gcggatcagc 720
aattgtgtcg ctgactattc cgtcctgtac aactctgcct ccttttctac cttcaagtgc 780
tacggcgtct cgcctaccaa gctgaacgac ctgtgcttca ccaacgtgta cgctgattcc 840
ttcgtgatca gaggcgacga agtccggcag atcgccccag gccaaaccgg aaacattgcc 900
gactacaact acaaactccc tgacgacttc accggctgcg ttatcgcctg gaactccaac 960
aacctggact ccaaggtggg cggcaactac aactacctgt accggctgtt cagaaagtct 1020
aatctgaagc ctttcgagag agacatctcc accgagatct accaggccgg ctccaccccg 1080
tgcaacggcg tgaagggctt caactgctat ttccccctgc agtcctacgg ctttcagccc 1140
acctacggcg tgggctacca accttacaga gtcgtcgtgc tgagcttcga actgcttcac 1200
gcccctgcta ccgtgtgcgg cccaaagaaa tctacaaacc tggtcaagaa caagtgcgtg 1260
aacttcgagc ccaagtcctg tgacaaaact cacacctgtc ctccttgccc tgcccccgaa 1320
ctgctgggag gcccctccgt gtttctgttc ccacctaagc ctaaggacca gctgatgatc 1380
tcccgcacac ccgaggtgac ctgtgtggtg gtcgacgtgt ctcatgagga tcctgaggtg 1440
aagttcaact ggtacgtgga tggcgtggaa gtgcacaacg ccaagacgaa gcccagagag 1500
gaacagtaca actccaccta cagagtggtg tccgtgctga cagttctgca ccaggactgg 1560
ctgaatggca aagagtacaa gtgcaaggtg tccaacaagg ctctgcccgc tcctatcgag 1620
aagacaatca gcaaggccaa aggccagcct agagagcctc aagtgtacac cctgcctcct 1680
tctagagatg agctgactaa gaaccaggtg tctctgacct gcctggtgaa gggcttctac 1740
ccttctgata tcgctgtgga atgggagtct aatggccagc ctgagaacaa ctacaagacc 1800
acccctccag tgctcgattc cgacggatct ttcttcctgt attccaagct gaccgtggac 1860
aagtccagat ggcagcaggg caacgtgttc tcctgctccg tgctgcacga ggccctgcat 1920
aaccactaca cccagaaatc tctgtccctg tctcctggca ag 1962
Claims (16)
1.一种治疗或预防与SARS-CoV-2相关的疾病或病状的疫苗组合产品,所述疫苗组合产品包含:
(i)亲本株疫苗,所述亲本株疫苗包含野生型SARS-CoV-2多肽的融合蛋白,所述野生型SARS-CoV-2融合蛋白包含:(1)干扰素或其功能片段;(2)野生型SARS-CoV-2的S蛋白的RBD或其功能片段;和(3)免疫球蛋白Fc区;和
(ii)突变株疫苗,所述突变株疫苗包含突变型SARS-CoV-2多肽的融合蛋白,所述突变型SARS-CoV-2融合蛋白包含:(1)干扰素或其功能片段;(2)突变型SARS-CoV-2的S蛋白的RBD或其功能片段;和(3)免疫球蛋白Fc区;
其中,所述亲本株疫苗或所述突变株疫苗中的一种作为引发疫苗施用,所述亲本株疫苗或所述突变株疫苗中的一种作为加强疫苗施用,并且所述亲本株疫苗和所述突变株疫苗两者均被施用。
2.亲本株疫苗和突变株疫苗在制备治疗或预防与SARS-CoV-2相关的疾病或病状的疫苗组合产品中的用途,所述疫苗组合产品包含:
(i)亲本株疫苗,所述亲本株疫苗包含野生型SARS-CoV-2多肽的融合蛋白,所述野生型SARS-CoV-2融合蛋白包含:(1)干扰素或其功能片段;(2)野生型SARS-CoV-2的S蛋白的RBD或其功能片段;和(3)免疫球蛋白Fc区;和
(ii)突变株疫苗,所述突变株疫苗包含突变型SARS-CoV-2多肽的融合蛋白,所述突变型SARS-CoV-2融合蛋白包含:(1)干扰素或其功能片段;(2)突变型SARS-CoV-2的S蛋白的RBD或其功能片段;和(3)免疫球蛋白Fc区;
其中所述亲本株疫苗或所述突变株疫苗中的一种作为引发疫苗施用,所述亲本株疫苗或所述突变株疫苗中的一种作为加强疫苗施用,并且所述亲本株疫苗和所述突变株疫苗两者均被施用。
3.一种在有相应需要的受试者中诱导针对SARS-CoV-2的免疫应答的方法,所述方法包括:
(i)向受试者施用亲本株疫苗,所述亲本株疫苗包含野生型SARS-CoV-2多肽的融合蛋白,所述野生型SARS-CoV-2融合蛋白包含:(1)干扰素或其功能片段;(2)野生型SARS-CoV-2的S蛋白的RBD或其功能片段;和(3)免疫球蛋白Fc区;和
(ii)向受试者施用突变株疫苗,所述突变株疫苗包含突变型SARS-CoV-2多肽的融合蛋白,所述突变型SARS-CoV-2融合蛋白包含:(1)干扰素或其功能片段;(2)突变型SARS-CoV-2的S蛋白的RBD或其功能片段;和(3)免疫球蛋白Fc区;
其中所述亲本株疫苗或所述突变株疫苗中的一种作为引发疫苗施用,所述亲本株疫苗或所述突变株疫苗中的一种作为加强疫苗施用,并且所述亲本株疫苗和所述突变株疫苗两者均被施用;
优选地,所述受试者是哺乳动物或鸟类;
优选地,所述受试者是人类、牛、犬、猫、山羊、绵羊、猪、马、火鸡、鸭或鸡。
4.权利要求1所述的疫苗组合产品、权利要求2所述的用途或权利要求3所述的方法,其中,所述干扰素选自I型干扰素、II型干扰素和/或III型干扰素;
优选地,所述干扰素可来自人源或鼠源;
优选地,所述I型干扰素选自IFN-α、IFN-β、IFN-κ、IFN-δ、IFN-ε、IFN-τ、IFN-ω和IFN-ζ;
优选地,所述II型干扰素为干扰素γ;
优选地,所述III型干扰素选自IFN-λ1(IL-29)、IFN-λ2(IL-28a)和IFN-λ(IL-28b);
优选地,所述干扰素选自人IFN-α1、IFN-α2、IFN-α4、IFN-α5、IFN-α6、IFN-α7、IFN-α8、IFN-α10、IFN-α13、IFN-α14、IFN-α16、IFN-α17和IFN-α21;
更优选地,所述干扰素为IFN-α2a;优选地,所述IFN-α2a的氨基酸序列包含与SEQ IDNO 1所示氨基酸序列具有80%或以上同一性的氨基酸序列,优选具有85%、90%、95%、96%、97%、98%、99%以上同一性的氨基酸序列,更优选具有98%或99%以上同一性的氨基酸序列;更优选地,所述IFN-α-2a的氨基酸序列如SEQ ID NO:1所示。
5.根据权利要求1或4所述的疫苗组合产品、权利要求2或4所述的用途或权利要求3或4所述的方法,其中,所述野生型SARS-CoV-2的S蛋白的RBD包含与SEQ ID NO 2所示的氨基酸序列具有80%或以上同一性的氨基酸序列,优选具有85%、90%、95%、96%、97%、98%、99%以上同一性的氨基酸序列,更优选具有98%或99%以上同一性的氨基酸序列;更优选地,所述野生型SARS-CoV-2的S蛋白的RBD的氨基酸序列如SEQ ID NO:2所示;
优选地,所述突变型SARS-CoV-2的S蛋白的RBD包含与SEQ ID NO 3所示的氨基酸序列具有80%或以上同一性的氨基酸序列,优选具有85%、90%、95%、96%、97%、98%、99%以上同一性的氨基酸序列,更优选具有98%或99%以上同一性的氨基酸序列;更优选地,所述突变型SARS-CoV-2的S蛋白的RBD的氨基酸序列如SEQ ID NO:3所示。
6.根据权利要求1、4或5任一项所述的疫苗组合产品、权利要求2、4或5任一项所述的用途或权利要求3-5任一项所述的方法,其中,所述免疫球蛋白Fc区选自IgG1、IgG2、IgG3和/或IgG4的恒定区氨基酸序列;
优选地,所述免疫球蛋白Fc区为IgG1的Fc区;优选地,所述IgG1 Fc区包含与SEQ ID NO4所示氨基酸序列具有80%或以上同一性的氨基酸序列,优选具有85%、90%、95%、96%、97%、98%、99%以上同一性的氨基酸序列,更优选具有98%或99%以上同一性的氨基酸序列;更优选地,所述IgG1Fc区的氨基酸序列如SEQ ID NO 4所示。
7.根据权利要求1、4-6任一项所述的疫苗组合产品、权利要求2、4-6任一项所述的用途或权利要求3-6任一项所述的方法,其中,所述融合蛋白还包含一个或多个Th细胞辅助表位和/或连接片段;
优选地,所述Th细胞辅助表位为PADRE或其衍生物;所述PADRE或其衍生物的氨基酸序列选自SEQ ID NO 5、SEQ ID NO 6、SEQ ID NO 7、SEQ ID NO 8、SEQ ID NO 9和SEQ ID NO10;
优选地,所述连接片段为柔多肽序列;优选地,所述柔性肽的氨基酸序列选自SEQ IDNO 11和SEQ ID NO 12。
8.根据权利要求1、4-7任一项所述的疫苗组合产品、权利要求2、4-7任一项所述的用途或权利要求3-7任一项所述的方法,其中,所述亲本株疫苗和/或所述突变株疫苗独立地还包含一种或更多种药学上可接受的载体、赋形剂、稀释剂或佐剂;
优选地,所述佐剂选自氢氧化铝、磷酸铝、皂苷例如Quil A、QS-21、GPI-0100、油包水型乳状液、水包油型乳状液、水包油包水型乳状液;
优选地,其中所述亲本株疫苗和/或所述突变株疫苗呈液体、乳液、固体、气雾剂、薄雾或气体的形式;
优选地,所述野生型SARS-CoV-2的融合蛋白包含与选自SEQ ID NO 13所示氨基酸序列具有80%或以上同一性的氨基酸序列,优选具有85%、90%、95%、96%、97%、98%、99%以上同一性的氨基酸序列,更优选具有98%或99%以上同一性的氨基酸序列;优选地,所述野生型SARS-CoV-2的融合蛋白的氨基酸序列如SEQ ID NO 13所示;
优选地,所述突变型SARS-CoV-2的融合蛋白包含与选自SEQ ID NO 14所示氨基酸序列具有80%或以上同一性的氨基酸序列,优选具有85%、90%、95%、96%、97%、98%、99%以上同一性的氨基酸序列,更优选具有98%或99%以上同一性的氨基酸序列;优选地,所述突变型SARS-CoV-2的融合蛋白的氨基酸序列如SEQ ID NO 14所示;
优选地,所述突变株疫苗是引发疫苗,并且所述亲本株疫苗是加强疫苗;
优选地,所述亲本株疫苗是引发疫苗,并且所述突变株疫苗是加强疫苗;
优选地,所述加强疫苗在所述引发疫苗初始给予后间隔一段时间给予以进行免疫;
优选地,所述加强疫苗在所述引发疫苗初始给予后间隔一段时间首次给予以进行第一次加强免疫,并且,所述加强疫苗在引发疫苗初始给予后间隔另一段时间再次给予以进行第二次加强免疫;优选地,所述亲本株疫苗是引发疫苗,并且所述突变株疫苗是加强疫苗,所述突变株疫苗在所述亲本株疫苗初始给予后间隔一段时间首次给予,并且,所述突变株疫苗在亲本株疫苗初始给予后间隔另一段时间再次给予;
优选地,所述引发疫苗在所述引发疫苗初始给予后间隔一段时间再次给予以进行第一次加强免疫,并且,所述加强疫苗在引发疫苗初始给予后间隔另一段时间首次给予以进行第二次加强免疫;优选地,所述亲本株疫苗是引发疫苗,并且所述突变株疫苗是加强疫苗,所述亲本株疫苗在所述亲本株疫苗初始给予后间隔一段时间再次给予,并且,所述突变株疫苗在亲本株疫苗初始给予后间隔另一段时间首次给予;
优选地,所述加强疫苗在所述引发疫苗初始给予后大约1-10周给予,优选2-8、3-8、1-3、2-5、2-3、3-5、5-8周给予,更优选2-8、2-5,3-5周给予;
更优选地,所述加强疫苗在所述引发疫苗初始给予后大约1-10周首次给予,优选2-8、3-8、1-3、2-5、2-3、3-5、5-8周首次给予,更优选2-8、2-5,3-5周首次给予;所述加强疫苗在所述引发疫苗初始给予后大约4-72周再次给予,优选6-52、6-45、6-30、6-25、8-52、8-30、8-25、4-12周,更优选4-12、6-25、8-25周再次给予;
更优选地,所述引发疫苗在所述引发疫苗初始给予后大约1-10周再次给予,优选2-8、3-8、1-3、2-5、2-3、3-5、5-8周再次给予,更优选2-8、2-5,3-5周再次给予;所述加强疫苗在所述引发疫苗初始给予后大约4-72周首次给予,优选6-52、6-45、6-30、6-25、8-52、8-30、8-25、4-12周,更优选4-12、6-25、8-25周首次给予;
更优选地,所述加强疫苗在所述引发疫苗初始给予后大约2-5周首次给予,并在所述引发疫苗初始给予后大约6-25周再次给予;
更优选地,所述引发疫苗在所述引发疫苗初始给予后大约2-5周再次给予,所述加强疫苗在所述引发疫苗初始给予后大约6-25周首次给予。
9.编码1、4-7任一项所述的疫苗组合产品的核酸;
优选地,所述包含野生型SARS-CoV-2多肽融合蛋白的编码核酸包含与SEQ ID NO:15所示核苷酸序列具有80%或以上同一性的核苷酸序列,优选具有85%、90%、95%、96%、97%、98%、99%以上同一性的核苷酸列,更优选具有98%或99%以上同一性的核苷酸序列;所述野生型SARS-CoV-2的融合蛋白的编码核酸为SEQ ID NO 15所示的核酸;
优选地,所述包含突变型SARS-CoV-2多肽融合蛋白的编码核酸包含与SEQ ID NO:16所示核苷酸序列具有80%或以上同一性的核苷酸序列,优选具有85%、90%、95%、96%、97%、98%、99%以上同一性的核苷酸列,更优选具有98%或99%以上同一性的核苷酸序列;所述突变型SARS-CoV-2融合蛋白的编码核酸为SEQ ID NO 16所示的核酸;
优选地,所述核酸是mRNA。
10.一种包含权利要求9所述的核酸的表达载体;
优选地,所述表达载体选自质粒、粘粒、病毒载体、RNA载体或线性或圆形DNA或RNA分子;
优选地,所述质粒选自pCI、puc57、pcDNA3、pSG5、pJ603和pCMV;
优选地,所述病毒载体选自腺病毒、逆转录病毒、细小病毒(例如,腺伴随病毒)、冠状病毒、负链RNA病毒诸如正粘病毒(例如,流感病毒)、弹状病毒(例如,狂犬病和水疱性口炎病毒)、副粘病毒(例如,麻疼和仙台)、正链RNA病毒诸如小RNA病毒和甲病毒,和双链DNA病毒;
优选地,所述腺病毒载体选自人、黑猩猩或恒河猴腺病毒;优选地,所述腺病毒选自血清型Ad2、Ad4、Ad5、Ad6、Ad11、Ad12、Ad24、Ad26、Ad34、Ad35、Ad40、Ad48、Ad49、Ad50、Ad52和Pan9腺病毒;
优选地,所述逆转录病毒选自禽造白细胞组织增生-肉瘤、哺乳动物C-型、B-型病毒、D-型病毒、HTLV-BLV集合、慢病毒和泡沫病毒;
优选地,所述慢病毒载体选自HIV-1、HIV_2、SIV、FIV、BIV、EIAV、CAEV和绵羊脱髓鞘性脑白质炎慢病毒;
优选地,所述双链DNA病毒包括腺病毒、疱疹病毒(例如,单纯疱疹病毒1和2型、愛泼斯坦-巴尔病毒、巨细胞病毒)和痘病毒(例如,牛痘病毒、鸡痘病毒和金丝雀痘病毒)、诺沃克病毒、披膜病毒、黄病毒、呼肠孤病毒、乳多泡病毒、嗜肝DNA病毒、杆状病毒和肝炎病毒。
11.一种表达权利要求1、4-7任一项所述的疫苗组合产品、包含权利要求9所述的核酸和/或包含权利要求10所述的表达载体的宿主细胞;
优选地,所述宿主细胞是原核细胞或真核细胞;
优选地,所述原核细胞是细菌细胞;优选地,所述原核细胞是大肠杆菌细胞;
优选地,所述真核细胞选自酵母细胞、昆虫细胞和哺乳动物细胞;优选地,所述哺乳动物细胞选自CHO、HEK293、SP2/0、BHK、C127等;更优选地,所述真核细胞为CHO细胞。
12.一种药物组合物,其包含权利要求1、4-7任一项所述的疫苗组合产品、权利要求9所述的核酸、权利要求10所述的表达载体和/或权利要求11所述的宿主细胞,以及任选地一种或多种药学上可接受载体、稀释剂或赋形剂。
13.一种试剂盒,其包含权利要求1-8任一项所述的疫苗组合产品、权利要求9所述的核酸、权利要求10所述的表达载体、权利要求11所述的宿主细胞和/或权利要求12所述的药物组合物。
14.成套药盒,其包括以下组分:
亲本株疫苗,与药学上可接受载体、稀释剂或赋形剂联合;
突变株疫苗,与药学上可接受载体、稀释剂或赋形剂联合;
其中所述组分以分开施用的形式提供。
15.权利要求14所述成套药盒,其包括:
含亲本株疫苗与药学上可接受载体、稀释剂或赋形剂的第一容器;和含突变株疫苗与药学上可接受载体、稀释剂或赋形剂的第二容器。
16.权利要求12所述的药物组合物、权利要求13所述的试剂盒或权利要求14或15所述的成套药盒在制备用于在有相应需要的受试者中诱导针对SARS-CoV-2的免疫应答的药物组合物中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111051170.9A CN115770292A (zh) | 2021-09-08 | 2021-09-08 | 新型冠状病毒SARS-CoV-2的协同免疫及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111051170.9A CN115770292A (zh) | 2021-09-08 | 2021-09-08 | 新型冠状病毒SARS-CoV-2的协同免疫及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115770292A true CN115770292A (zh) | 2023-03-10 |
Family
ID=85388111
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111051170.9A Pending CN115770292A (zh) | 2021-09-08 | 2021-09-08 | 新型冠状病毒SARS-CoV-2的协同免疫及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115770292A (zh) |
-
2021
- 2021-09-08 CN CN202111051170.9A patent/CN115770292A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4163291A1 (en) | Polypeptide vaccine coupled with tlr7 agonist for novel coronavirus and use thereof | |
CA2526128C (en) | Severe acute respiratory syndrome dna vaccine compositions and methods of use | |
US10059747B2 (en) | Crimean-congo haemorrhagic fever virus antigenic composition | |
US10611801B2 (en) | Compositions and methods for preventing and treating Zika virus infection | |
KR20210133888A (ko) | 사스-코로나바이러스-2 감염증 예방 또는 치료용 백신 조성물 | |
WO2023036191A1 (zh) | 新型冠状病毒SARS-CoV-2的Delta变异株疫苗与应用 | |
ES2640961T3 (es) | Virus de la estomatitis vesicular para vacunas de sensibilización y refuerzo | |
US7335727B2 (en) | Pharmaceutical used for treating HIV infection, the composition and uses thereof | |
KR20140122258A (ko) | Rsv 감염의 예방 및 치료를 위한 혼합 항원 및 dna 백신 | |
CN115246874A (zh) | 一种重组新型冠状病毒s-rbd三聚体蛋白、其制备方法和应用 | |
EP4034548A1 (en) | Coronavirus vaccines and uses thereof | |
JP2021529538A (ja) | 重症熱性血小板減少症候群(sfts)ウイルス感染疾患の予防または治療用ワクチン組成物 | |
EP3013852A1 (en) | Methods and compositions for dengue virus vaccines | |
KR20230005265A (ko) | Sars-cov-2에 대한 백신 및 이의 제조 | |
KR20190134578A (ko) | HBD2(human beta-defensin 2) 또는 상기 유전자와 융합된 메르스 코로나 바이러스의 에피토프 단백질을 포함하는 메르스 코로나바이러스의 예방 또는 치료용 조성물 | |
CN115770292A (zh) | 新型冠状病毒SARS-CoV-2的协同免疫及其用途 | |
CN117003885A (zh) | H5n8禽流感广谱性疫苗的开发及其应用 | |
CN115770291A (zh) | 新型冠状病毒SARS-CoV-2疫苗加强免疫及其应用 | |
KR20070019223A (ko) | 최적화된 유전자 코돈을 가지는 e7 유전자 및 라이소좀타겟팅 시그널 서열을 포함하는 파필로마바이러스 유발질환의 예방 또는 치료용 조성물 | |
KR20220133633A (ko) | SARS-CoV-2 스파이크 단백질 S1 유래 단백질 및 페리틴 유래 단백질을 포함하는 재조합 단백질 및 이의 용도 | |
KR100768051B1 (ko) | 간염 바이러스 orf2의 n-말단 영역으로부터 유래한프로세싱 성분 및 항원성 폴리펩티드를 암호화하는 핵산구성물 | |
EP3993873A1 (en) | Mammary tumor virus suppression | |
KR102604839B1 (ko) | Prrsv 유래 펩타이드를 포함하는 면역원성 조성물 | |
CN113185586B (zh) | SARS-CoV-2编码蛋白来源的T细胞表位多肽及其应用 | |
US20240189418A1 (en) | Virus vaccine based on virus surface engineering providing increased immunity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Chen Xi Inventor after: Feng Chunyan Inventor after: Ai Junwen Inventor after: Hu Zhenxiang Inventor after: Yang Jiaming Inventor before: Chen Xi Inventor before: Feng Chunyan Inventor before: Ai Junwen Inventor before: Hu Zhenxiang Inventor before: Yang Jiaming |
|
CB03 | Change of inventor or designer information |